var title_f23_37_24144="Insect sting reaction PI";
var content_f23_37_24144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insect sting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a normal reaction to a bee or wasp sting. There is usually some redness and mild, painful swelling around the spot where the stinger went in. These symptoms usually go away within a few hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Theodore Freeman.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24144=[""].join("\n");
var outline_f23_37_24144=null;
var title_f23_37_24145="Patient information: Orbital cellulitis (The Basics)";
var content_f23_37_24145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/84001\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/6/14438\">",
"         Orbital cellulitis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/62/10210\">",
"          Sinuses of the face",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Orbital cellulitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/orbital-cellulitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7897832\">",
"      <span class=\"h1\">",
"       What is orbital cellulitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Orbital cellulitis is a rare but dangerous infection that affects the tissues around the eyeball (",
"      <a class=\"graphic graphic_figure graphicRef83862 \" href=\"UTD.htm?14/6/14438\">",
"       figure 1",
"      </a>",
"      ). It can lead to blindness and, very rarely, death.",
"     </p>",
"     <p>",
"      Orbital cellulitis can happen when bacteria get into the tissues around the eyeball. Most cases happen in people who have sinusitis. Sinusitis is an infection of the sinuses, the hollow areas in the bones of the face (",
"      <a class=\"graphic graphic_figure graphicRef75045 \" href=\"UTD.htm?9/62/10210\">",
"       figure 2",
"      </a>",
"      ). It can also happen if a person has:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eye surgery or an injury near the eye",
"       </li>",
"       <li>",
"        A blocked tear duct",
"       </li>",
"       <li>",
"        An infection in a tooth, an ear, or somewhere in the face",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A more common eye infection is called &ldquo;preseptal cellulitis&rdquo; or &ldquo;periorbital cellulitis.&rdquo; This is different from orbital cellulitis, but it has some of the same symptoms. These include eye pain and swollen, red eyelids. But preseptal cellulitis affects only the eyelid and is not as serious as orbital cellulitis. Orbital cellulitis affects the deeper tissues around the eyeball, though the eyelid can be affected, too.",
"     </p>",
"     <p>",
"      Both orbital cellulitis and preseptal cellulitis are most common in young children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7897847\">",
"      <span class=\"h1\">",
"       What are the symptoms of orbital cellulitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eyelid swelling and redness",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Double vision",
"       </li>",
"       <li>",
"        Problems with the eyeball. It might:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Hurt a lot, especially when you try to move it",
"       </li>",
"       <li>",
"        Not move at all",
"       </li>",
"       <li>",
"        Bulge outward",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7897862\">",
"      <span class=\"h1\">",
"       Is there a test for orbital cellulitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will do an exam and ask about your symptoms. You will probably need an imaging test such as an MRI or CT scan. These tests take pictures of the inside of the head, including the eyes and sinuses.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7897877\">",
"      <span class=\"h1\">",
"       How is orbital cellulitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotics &ndash; Antibiotics are medicines that treat infections caused by bacteria. Antibiotics for orbital cellulitis are given into a vein through a small tube called an &ldquo;IV.&rdquo; Usually, people who get them start to get better in about 3 to 5 days. Once you start getting better, you can switch to antibiotic pills. You will need to take these for at least 2 to 3 weeks and maybe longer.",
"       </li>",
"       <li>",
"        Surgery &ndash; This is done only if:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        An imaging tests shows signs of an &ldquo;abscess.&rdquo; An abscess is a pocket of pus inside the head near the eye. The surgery removes the abscess.",
"       </li>",
"       <li>",
"        You do not show any signs of getting better after taking antibiotics.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7897892\">",
"      <span class=\"h1\">",
"       Can orbital cellulitis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting orbital cellulitis by seeing your doctor or nurse if you have a serious case of sinusitis.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/37/24145?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 84001 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24145=[""].join("\n");
var outline_f23_37_24145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7897832\">",
"      What is orbital cellulitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7897847\">",
"      What are the symptoms of orbital cellulitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7897862\">",
"      Is there a test for orbital cellulitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7897877\">",
"      How is orbital cellulitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7897892\">",
"      Can orbital cellulitis be prevented?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/84001\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/6/14438\">",
"      Orbital cellulitis",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/62/10210\">",
"       Sinuses of the face",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_37_24146="Dissection of recurrent laryngeal nerve lateral view";
var content_f23_37_24146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Dissection of recurrent laryngeal nerve lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 550px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomy of recurrent laryngeal nerve and parathyroid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24146=[""].join("\n");
var outline_f23_37_24146=null;
var title_f23_37_24147="Superficial spreading melanoma 5";
var content_f23_37_24147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial spreading melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superficial spreading melanoma on the left posterior leg of a 29-year-old woman.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24147=[""].join("\n");
var outline_f23_37_24147=null;
var title_f23_37_24148="Tetracaine (systemic): Drug information";
var content_f23_37_24148=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetracaine (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/8/38019?source=see_link\">",
"    see \"Tetracaine (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/8/43138?source=see_link\">",
"    see \"Tetracaine (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9564871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pontocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9591208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9565167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Spinal anesthesia:",
"     </b>",
"     Injection:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage varies with the anesthetic procedure, the degree of anesthesia required, and the individual patient response; it is administered by subarachnoid injection for spinal anesthesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Perineal anesthesia:",
"     </i>",
"     5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Perineal and lower extremities:",
"     </i>",
"     10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Anesthesia extending up to costal margin:",
"     </i>",
"     15 mg; doses up to 20 mg may be given, but are reserved for exceptional cases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Low spinal anesthesia (saddle block):",
"     </i>",
"     2-5 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9565168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9565208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 1% [10 mg/mL] (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9564879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9565170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before injection, withdraw syringe plunger to make sure injection is not into vein or artery.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9564882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Spinal anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9565126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"     <b>",
"      Note:",
"     </b>",
"     Adverse effects listed are those characteristics of local anesthetics. Systemic adverse effects are generally associated with excessive doses or rapid absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, convulsions, dizziness, drowsiness, nervousness, unconsciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, pupil constriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9564887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tetracaine, ester-type anesthetics, aminobenzoic acid, or any component of the formulation; injection should not be used when spinal anesthesia is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9564888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, including rhythm disturbances, shock, or heart block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased plasma esterase levels: Use with caution in patients with abnormal or decreased levels of plasma esterases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill patients; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obstetric patients: Use with caution in obstetric patients; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients with increased intra-abdominal pressure: Use with caution in patients with increased intra-abdominal pressure; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Dental practitioners and/or clinicians using local anesthetic agents should be well-trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9565129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9564884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9564885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9564886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17917023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tetracaine (systemic) is excreted in breast milk. The manufacturer recommends that caution be exercised when administering tetracaine (systemic) to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pontocaine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (2 mL): $5.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tetracaine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (2 mL): $9.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Pontocaine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $14.62",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9565158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ester local anesthetic blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9565160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; detoxified by plasma esterases to aminobenzoic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Corcoran W, Butterworth J, Weller RS, et al, &ldquo;Local Anesthetic-Induced Cardiac Toxicity: A Survey of Contemporary Practice Strategies Among Academic Anesthesiology Departments,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2006, 103(5):1322-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24148/abstract-text/17056977/pubmed\" id=\"17056977\" target=\"_blank\">",
"        17056977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dix SK, Rosner GF, Nayar M, et al, &ldquo;Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2011, 39(4):872-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24148/abstract-text/21263316/pubmed\" id=\"21263316\" target=\"_blank\">",
"        21263316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foxall G, McCahon R, Lamb J, et al, &ldquo;Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2007, 62(5):516-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24148/abstract-text/17448066/pubmed\" id=\"17448066\" target=\"_blank\">",
"        17448066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gregory PJ and Matsuda K, &ldquo;Cetacaine Spray-Induced Methemoglobinemia After Transesophageal Echocardiography,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(9):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24148/abstract-text/10981258/pubmed\" id=\"10981258\" target=\"_blank\">",
"        10981258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lavergne S, Darmon M, Levy V, et al, &ldquo;Methemoglobinemia and Acute Hemolysis After Tetracaine Lozenge Use,\"",
"      <i>",
"       J Crit Care",
"      </i>",
"      , 2006, 21(1):112-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24148/abstract-text/16616636/pubmed\" id=\"16616636\" target=\"_blank\">",
"        16616636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Litz RJ, Popp M, Stehr SN, et al, &ldquo;Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion,\"",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2006, 61(8):800-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24148/abstract-text/16867094/pubmed\" id=\"16867094\" target=\"_blank\">",
"        16867094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo JM, Dasta JF, Kleinschmidt KC, et al, &ldquo;State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2010, 44(4):688-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24148/abstract-text/20332339/pubmed\" id=\"20332339\" target=\"_blank\">",
"        20332339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenblatt MA, Abel M, Fischer GW, et al, &ldquo;Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2006, 105(1):217-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24148/abstract-text/16810015/pubmed\" id=\"16810015\" target=\"_blank\">",
"        16810015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandza JG Jr, Roberts RW, Shaw RC, et al, &ldquo;Symptomatic Methemoglobinemia With a Commonly Used Topical Anesthetic, Cetacaine,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1980, 30(2):187-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24148/abstract-text/6968187/pubmed\" id=\"6968187\" target=\"_blank\">",
"        6968187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Kan JH, Egberts AC, Rijnvos WP, et al, &ldquo;Tetracaine Versus Lidocaine-Prilocaine for Preventing Venipuncture-Induced Pain in Children,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(4):388-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24148/abstract-text/9043560/pubmed\" id=\"9043560\" target=\"_blank\">",
"        9043560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9931 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-C04F1AFADF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24148=[""].join("\n");
var outline_f23_37_24148=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564871\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9591208\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565167\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565168\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565208\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564879\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565170\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564882\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565126\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564887\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564888\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300123\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565129\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564884\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564885\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564886\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17917023\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322498\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565158\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565160\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9931\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9931|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/45/27347?source=related_link\">",
"      Tetracaine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/36/17987?source=related_link\">",
"      Tetracaine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/18/13603?source=related_link\">",
"      Tetracaine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/8/38019?source=related_link\">",
"      Tetracaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/8/43138?source=related_link\">",
"      Tetracaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/30/29155?source=related_link\">",
"      Tetracaine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/3/25652?source=related_link\">",
"      Tetracaine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/31/2547?source=related_link\">",
"      Tetracaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_37_24149="Hepatic hemangioma Light";
var content_f23_37_24149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cavernous hepatic hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple vascular channels of various sizes lined by a single layer of flattened endothelium and supported by thin fibrous septae (hematoxylin and eosin).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Imad Nasser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24149=[""].join("\n");
var outline_f23_37_24149=null;
var title_f23_37_24150="Hysterosalpingography";
var content_f23_37_24150=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hysterosalpingography",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/37/24150/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/37/24150/contributors\">",
"     Theodore A Baramki, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/37/24150/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/37/24150/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/37/24150/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/37/24150/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/37/24150/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterosalpingography (HSG) refers to the radiographic evaluation of the uterine cavity and fallopian tubes after injection of a radio-opaque medium through the cervical canal. Fluoroscopy with image intensification is performed to improve the quality of the radiographic images, as well as help guide the procedure.",
"   </p>",
"   <p>",
"    Information obtained by HSG includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact\">",
"     <li>",
"      The width of the cervical canal",
"     </li>",
"     <li>",
"      The contour of the uterine cavity",
"     </li>",
"     <li>",
"      An outline of the lumen of the fallopian tubes and cornua",
"     </li>",
"     <li>",
"      The presence or absence of spillage of contrast from the fimbriated ends of the tubes",
"     </li>",
"     <li>",
"      An outline of peritoneal structures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to diagnostic information, HSG also has therapeutic effects, which are associated with increased fecundability in the months after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/1\">",
"     1",
"    </a>",
"    ]. Purported mechanisms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact\">",
"     <li>",
"      Mechanically dislodging substances (mucus, cellular debris) obstructing the fallopian tubes",
"     </li>",
"     <li>",
"      Enhancing endometrial receptivity",
"     </li>",
"     <li>",
"      Oil media may affect peritoneal macrophages by decreasing in vitro phagocytosis of sperm and altering interleukin and prostaglandin production",
"     </li>",
"     <li>",
"      Breaking down peritoneal adhesions that restrict tubal movement",
"     </li>",
"     <li>",
"      Stimulating tubal cilia, and thus enhancing transport of gametes",
"     </li>",
"     <li>",
"      Improving cervical mucus to enhance passage of sperm",
"     </li>",
"     <li>",
"      Iodine in the contrast medium has a bacteriostatic effect on mucous membranes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hysterosalpingography is discussed in this topic review. Other methods for assessing the uterine cavity are addressed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=see_link\">",
"     \"Saline infusion sonohysterography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link\">",
"     \"Overview of hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSG is typically performed as part of an infertility work-up or in the evaluation of recurrent early pregnancy loss or preterm delivery. Rarely, it is done to confirm tubal patency after reversal of tubal ligation or to confirm tubal occlusion after surgical sterilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=see_link\">",
"     \"Causes of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26679?source=see_link\">",
"     \"Evaluation of couples with recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HSG is helpful in detecting uterine anomalies, endometrial polyps, submucous myoma, and synechiae. It will detect several tubal abnormalities, including cornual occlusion, salpingitis isthmica nodosa, and hydrosalpinx.",
"   </p>",
"   <p>",
"    HSG provides little or no information about the outer contour of the uterus, ovaries, or pelvis; therefore, laparoscopy, magnetic resonance imaging, sonohysterography, or ultrasound examination may be needed to further evaluate some uterine anomalies, ovarian disorders, or peritubal pathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=see_link\">",
"     \"Saline infusion sonohysterography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HSG should not be performed if active infection is suspected anywhere in the pelvis or in the",
"    <span class=\"nowrap\">",
"     cervix/vagina,",
"    </span>",
"    or if there is active bleeding. Pregnancy is an absolute contraindication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TIMING",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSG should be done during the follicular phase of the cycle to minimize the chance of interfering with a possible early pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Jarcho cannula is the most common instrument used for injecting the radio-opaque medium, and the instrument I prefer. The cannula is metal with a rubber acorn placed close to the tip to prevent media from leaking out of the uterus. The instrument is stabilized by hooking it to a single-tooth tenaculum applied to the anterior lip of the cervix.",
"   </p>",
"   <p>",
"    Another option is use of an HSG catheter (REDI-TECH, Atlanta, GA), which is a plastic catheter with a balloon close to the tip. After insertion into the uterine cavity, the balloon is inflated with 1.5 mL of air and pulled down to the internal cervical os to create a seal. Some centers use suction cups applied to the cervix to give an airtight application [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/2\">",
"     2",
"    </a>",
"    ]. Advantages of using a catheter are that it can usually be passed through the cervical canal and managed without the need for a tenaculum, it is generally less uncomfortable for the patient, and it allows her to rotate her body more easily during the procedure if a position change is needed.",
"   </p>",
"   <p>",
"    Additional equipment consists of sterile drapes and gloves, sponge forceps, a cotton ball or gauze, povidone-iodine, sterile speculum, 10 mL syringe, single tooth tenaculum, and contrast media.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic HSG was originally performed with oil soluble contrast media, but was gradually replaced by water soluble contrast media because of lower cost; better imaging of the tubal mucosa; more prompt demonstration of tubal patency; less likelihood of persistence of contrast medium within the pelvic cavity; reduction of complications such as intravasation resulting in allergic reactions; and reduction in long-term lipogranuloma formation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Most clinicians use water-soluble media for these reasons. However, water soluble contrast appears to cause more pain because it distends the fallopian tubes and uterus more rapidly than the high viscosity oil soluble media and is more irritating to the peritoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There were several reports of deaths after the use of oily media for imaging studies before the use of fluoroscopy screening, but none have been reported since use of fluoroscopy; therefore, the use of oil soluble contrast media for HSG under fluoroscopy is not unreasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/4\">",
"     4",
"    </a>",
"    ]. However, there is no good evidence that oil-soluble media is more effective than water-soluble media [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATIENT PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is usually asked to empty her bladder just before the procedure. However, some clinicians feel that better visualization is achieved with full bladder and that a full bladder helps to deflex an anteverted uterus when only limited traction can be applied with a soft cannula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;We ask the patient to take a nonsteroidal antiinflammatory drug (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    600 mg) orally one hour before the procedure; however, there are no high quality data showing that analgesics significantly prevent or reduce cramping and muscle spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Some randomized trials have reported less procedure-associated pain with use of intravenous opioids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/7\">",
"     7",
"    </a>",
"    ]) or topical anesthetics [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/8\">",
"     8",
"    </a>",
"    ]. Both of these interventions are costly and take time to",
"    <span class=\"nowrap\">",
"     set-up/administer;",
"    </span>",
"    for most patients, no anesthesia or sedation is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists recommends antibiotic prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg two times per day for five days) if HSG demonstrates dilated fallopian tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The antibiotic can be started preprocedure in patients with a history of pelvic inflammatory disease. The antibiotic is discontinued postprocedure if the fallopian tubes are normal at HSG, and continued if they are dilated. Antibiotic prophylaxis is not warranted in women with no history of pelvic inflammatory disease and normal fallopian tubes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Contrast allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to make sure that the patient does not have a history of allergy to contrast media or iodinated agents. In patients with known allergy, prophylactic measures may include use of",
"    <span class=\"nowrap\">",
"     nonionic/low",
"    </span>",
"    osmolarity contrast media or gadolinium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]; alternatively, a patient can be premedicated with oral steroids starting the day before HSG, or intravenous steroids if an allergy is discovered just before the procedure. Some clinicians also give an intravenous antihistamine in combination with the steroids. It is advisable to consult with an allergist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiologist. Shellfish allergy does not increase the risk of iodine contrast allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure is performed in a radiology suite with a radiologist in attendance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The position of the uterus (anteverted, retroverted, axial) should be confirmed by bimanual examination. The adnexae are also evaluated for masses or pain.",
"   </p>",
"   <p>",
"    The patient lies on the x-ray table, sterile drapes are applied to her perineum, and then a sterile speculum is inserted into the vagina to visualize the cervix. A cotton ball or gauze on a sponge holder is saturated with povidone-iodine solution and used to cleanse the cervix. A tenaculum may be placed on the anterior cervical lip at this time.",
"   </p>",
"   <p>",
"    Contrast should be passed through the instrument to expel as many air bubbles as possible before the cannula or catheter is inserted into the patient. Air bubbles in the uterine cavity may be misdiagnosed as an adhesion, submucous myoma, or a polyp. The cannula or catheter is then inserted through the cervical canal and the speculum is pulled out of the vagina so as not to obscure visualization of the cervical canal and lower uterine segment when radiographs are taken. If the uterus is extremely anteverted or retroverted, pulling on the tenaculum will bring the uterus axial and provide a much better view. With a metal cannula, traction also needs to be applied to prevent leakage from the os.",
"   </p>",
"   <p>",
"    The radio-opaque medium is injected slowly under fluoroscopy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81961 \" href=\"UTD.htm?21/10/21664\">",
"     image 1",
"    </a>",
"    ). It is advisable to take a radiograph after injection of 2 mL of medium to look for filling defects in the uterine cavity, such as polyps, submucous myomas or synechiae (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67493 graphicRef80816 graphicRef60263 \" href=\"UTD.htm?34/13/35031\">",
"     image 2A-C",
"    </a>",
"    ), which could be concealed by distending the uterus with contrast (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55045 \" href=\"UTD.htm?27/5/27743\">",
"     image 3",
"    </a>",
"    ). Further incremental injections will outline the cornua, isthmic, and ampullary portions of the tubes. A healthy ampullary portion of the tube shows rugal folds. The contrast should then spill from the ends of the tubes if they are patent. Collection of contrast around the distal end of a tube suggests peritubal adhesions. If significant pain occurs during the procedure, the injection is stopped for a few minutes followed by slower injection of contrast.",
"   </p>",
"   <p>",
"    In general, radiographs are taken at the beginning of uterine cavity filling, when the cavity is filled, during tubal filling to evaluate the tubal mucosa, and later to document whether there is spillage of contrast into the peritoneal cavity. A late film can be taken 20 minutes after removal of the cannula for evaluation of pelvic dispersion of the contrast medium if peritubal adhesions are suspected. Side views of the uterus and tubes may be obtained by having the patient change her position on the table.",
"   </p>",
"   <p>",
"    Fluoroscopy can detect small lesions or abnormalities that might be missed without real-time imaging. Fluoroscopy is also used to guide the volume of contrast that needs to be injected for optimum visualization. The average amount of contrast medium for a complete examination is about 5 to 6 ml. Excessive injection of contrast prevents proper interpretation of the study, while insufficient injection of contrast will result in an incomplete study (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81548 \" href=\"UTD.htm?40/42/41633\">",
"     image 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/13\">",
"     13",
"    </a>",
"    ]. As an example, excessive injection of contrast may result in spillage from a phimotic fimbrial end or in free pelvic dissemination suggesting bilateral patency even though there is only unilateral patency.",
"   </p>",
"   <p>",
"    The radiographs are examined to determine the size and shape of the uterus, whether there are filling defects, whether the endometrial surfaces are irregular or smooth, and whether there is normal spillage or abnormal pooling of medium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Technical problems and solutions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet\">",
"     <li>",
"      Leaking of contrast media: Use a larger cannula tip, apply forceful traction, or use a balloon catheter.",
"     </li>",
"     <li>",
"      Stenotic os: Use a smaller tip such as a pediatric Foley catheter or employ cervical dilators.",
"     </li>",
"     <li>",
"      Air bubbles in uterine cavity (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70355 \" href=\"UTD.htm?11/0/11264\">",
"       image 5",
"      </a>",
"      ): Observe the defects under fluoroscopy to look for movement, which helps to distinguish mobile bubbles from fixed structural abnormalities. Aspirate and refill the uterine cavity, which may remove air bubbles.",
"     </li>",
"     <li>",
"      Inadequate visualization of the uterine cavity: Put more outward traction on the cervix to bring the fundus into a more axial position (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79936 \" href=\"UTD.htm?19/18/19759\">",
"       image 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Nonfilling of one or both fallopian tubes may be due to tubal damage, obstruction, or cornual spasm. An obstructing mucous plug or other debris may be dislodged by constant pressure on the syringe. Spasm may be alleviated by rest followed by slower injection or intravenous injection of glucagon (1 mg). Spasm is characterized by a rounded smooth cornual margin whereas cornual occlusion is characterized by pointed or irregular cornual margin, although these changes are difficult to assess definitively [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/14\">",
"       14",
"      </a>",
"      ]. Obstruction may be due to infection, endometriosis, dried secretions, mucus plugs, or scarring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If unilateral blockage is visualized, one can inject 1 to 2 ml of contrast material until either spillage from the patent side obscures visualization or the previously nonvisualized tube fills and spills [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/15\">",
"     15",
"    </a>",
"    ]. Consistency of injection pressure and fluoroscopic guidance are important for accurately evaluating tubal patency.",
"   </p>",
"   <p>",
"    <ul class=\"bullet\">",
"     <li>",
"      Intravasation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61897 \" href=\"UTD.htm?13/13/13520\">",
"       image 7",
"      </a>",
"      ): Early intravasation into uterine and ovarian veins or lymphatics manifests as multiple thin ascending beaded channels on radiography. These channels can be identified by their anatomy, but can sometimes be mistaken for tubal filling. Avoiding inadvertent insertion of the cannula into the myometrium and excessive pressure during injection of contrast material minimizes the risk of intravasation.",
"     </li>",
"     <li>",
"      External artifacts: Abdominal structures (eg, air or stool in the colon) superimposed over the uterus can lead to misinterpretation of the HSG (",
"      <a class=\"graphic graphic_picture graphicRef73065 \" href=\"UTD.htm?34/54/35695\">",
"       picture 1",
"      </a>",
"      ). Moving the patient onto her side and taking another radiograph can help distinguish intrauterine from extrauterine structures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ACCURACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic accuracy is affected by factors such as the training and experience of the physician performing the procedure and interpreting the films, the underlying disease, and the standard used to validate HSG results. For these reasons, a wide range of values has been reported.",
"   </p>",
"   <p>",
"    In one well designed study of 756 patients undergoing HSG, tubal findings on HSG were classified as normal, abnormal, or suspicious (image without completely normal findings or without unambiguous bilateral distal tubal obstruction) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/16\">",
"     16",
"    </a>",
"    ]. Surgery with chromopertubation was subsequently performed for confirmation. The overall false-positive rate was 1.2 percent when only normal and abnormal HSG categories were considered, but rose to 28.8 percent when suspicious cases were included. The positive predictive value for bilateral distal tubal occlusion with or without hydrosalpinx (abnormal category) was 95.7 percent, the false-negative rate was 3.4 percent, and the negative predictive value was 96.6 percent. The authors concluded that HSG was reasonably accurate for patients with a normal study or distal tubal obstruction, but confirmatory testing was recommended for suspicious findings. Furthermore, the prevalence of pelvic disease in the normal HSG group was high enough to warrant diagnostic laparoscopy if nonsurgical treatment was unsuccessful.",
"   </p>",
"   <p>",
"    HSG is less accurate in diagnosis of uterine anomalies because it does not provide information about the external uterine contour. This is critical in distinguishing a septate uterus (smooth fundus) from uterus didelphys (indented fundus) and in diagnosis of an obstructed uterine horn. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amount of radiation exposure depends upon the equipment and factors such as duration of fluoroscopy, number of films, and size of the patient. The ovarian dose in most cases is less than 0.6 rad [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/17\">",
"     17",
"    </a>",
"    ]. For the 67 KVP, 1.9 mA and tube target-to-entrance skin distance of 18 inches fluoroscope, the permissible rad time limit is approximately 35 minutes if the radiation exposure to the ovary is limited to 10 rad [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24150/abstract/18\">",
"     18",
"    </a>",
"    ]. The dose can be reduced with digital fluoroscopy equipment that allows one to obtain hard copy film from stored digital images without need for further patient exposure.",
"   </p>",
"   <p>",
"    Complications of HSG are uncommon and include uterine perforation, infection, allergic reactions, and syncope. The rate of infection of the upper genital tract is about 1 percent, but is higher in women with history of pelvic inflammatory disease. There are rare reports of hemorrhage and shock, pulmonary or retinal embolus (only with oil media).",
"   </p>",
"   <p>",
"    HSG in women with endometrial cancer may disseminate tumor cells into the peritoneal cavity. Positive peritoneal washings mean the surgical stage will be at least IIIA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\"",
"    </a>",
"    .) However, the clinical significance of this finding is not known as transport of these cells does not necessarily result in implantation and persistence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     POSTPROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild pain is common during the procedure, and may last for a few hours afterwards. Treatment with nonsteroidal antiinflammatory drugs usually relieves this discomfort. Leaking of contrast and a small amount of bleeding from the vagina is common for a day or two after an HSG. Heavy bleeding, fever, or increasing pain is not normal and requires evaluation. Usual activities may be resumed immediately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet\">",
"     <li>",
"      Hysterosalpingography (HSG) is used both for diagnosis of uterine and tubal defects and for treatment of unexplained infertility. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major indications for HSG are infertility and recurrent pregnancy loss. The major contraindications are active pelvic infection, active bleeding, and pregnancy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSG should be done during the follicular phase, when pregnancy is unlikely. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most clinicians use water-soluble contrast media rather than oil contrast media because water soluble media has a better safety profile and produces higher quality visualization of tubal mucosa. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Media'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important preprocedure issues are ascertainment of allergy to contrast media, administration of a nonsteroidal antiinflammatory drug (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      600 mg) orally one hour prior to the procedure, and antibiotic prophylaxis (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg two times per day for three days starting the day prior to the procedure). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patient preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To prevent artifact, contrast should be passed through the instrument to expel as many air bubbles as possible before the cannula or catheter is inserted into the patient. The radio-opaque medium is injected slowly under fluoroscopy to prevent excessive injection of contrast, which will obscure visualization of small structures. Nonfilling of one or both fallopian tubes may be due to tubal damage, obstruction, or cornual spasm. An obstructing mucous plug or other debris may be dislodged by constant pressure on the syringe. Spasm may be alleviated by rest followed by slower injection or intravenous injection of glucagon (1 mg). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic accuracy is affected by factors such as the training and experience of the physician performing the procedure and interpreting the films, the underlying disease, and the standard used to validate HSG results. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic accuracy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications are uncommon and include uterine perforation, infection, allergic reactions, and syncope. Embolization has been reported with oil based contrast media injected without fluoroscopic guidance. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Side effects and complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/1\">",
"      Johnson N, Vandekerckhove P, Watson A, et al. Tubal flushing for subfertility. Cochrane Database Syst Rev 2005; :CD003718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/2\">",
"      Malstrom, T. A vacuum uterine cannula. Obstet Gynecol 1961; 18:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/3\">",
"      Johnson NP, Farquhar CM, Hadden WE, et al. The FLUSH trial--flushing with lipiodol for unexplained (and endometriosis-related) subfertility by hysterosalpingography: a randomized trial. Hum Reprod 2004; 19:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/4\">",
"      Lindequist S, Justesen P, Larsen C, Rasmussen F. Diagnostic quality and complications of hysterosalpingography: oil- versus water-soluble contrast media--a randomized prospective study. Radiology 1991; 179:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/5\">",
"      Ahmad G, Duffy J, Watson AJ. Pain relief in hysterosalpingography. Cochrane Database Syst Rev 2007; :CD006106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/6\">",
"      Anserinia, P. Strategies to minimize discomfort during diagnostic hysterosalpingography with disposable balloon catheters: a randomized placebo-controlled study with oral nonsteroidal premedication. Fertil Steril 2008; 90:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/7\">",
"      Cengiz M, Kafali H, Artuc H, Baysal Z. Opioid analgesia for hysterosalpingography: controlled double-blind prospective trial with remifentanil and placebo. Gynecol Obstet Invest 2006; 62:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/8\">",
"      Liberty G, Gal M, Halevy-Shalem T, et al. Lidocaine-prilocaine (EMLA) cream as analgesia for hysterosalpingography: a prospective, randomized, controlled, double blinded study. Hum Reprod 2007; 22:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/9\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 74. Antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2006; 108:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/10\">",
"      Pittaway DE, Winfield AC, Maxson W, et al. Prevention of acute pelvic inflammatory disease after hysterosalpingography: efficacy of doxycycline prophylaxis. Am J Obstet Gynecol 1983; 147:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/11\">",
"      Belt MM, Rodenko G, Taylor K, et al. Use of gadolinium for hysterosalpingography in iodine allergic women: a case-control study. Fertil Steril 2008; 90:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/12\">",
"      Silberzweig JE, Khorsandi AS, Caldon M, Alam S. Gadolinium for hysterosalpingography. J Reprod Med 2008; 53:15.",
"     </a>",
"    </li>",
"    <li>",
"     Siegler, A. Hysterosalpingography. In: Reproductive medicine and surgery. Wallach, E, Zacur, H (Eds), Mosby, Baltimore 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/14\">",
"      Horwitz RC, Morton PC, Shaff MI, Hugo P. A radiological approach to infertility--hysterosalpingography. Br J Radiol 1979; 52:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/15\">",
"      Siegler AM. Hysterosalpingography. Fertil Steril 1983; 40:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/16\">",
"      Opsahl MS, Miller B, Klein TA. The predictive value of hysterosalpingography for tubal and peritoneal infertility factors. Fertil Steril 1993; 60:444.",
"     </a>",
"    </li>",
"    <li>",
"     Ott, DJ, Fayez, JA. Hysterosalpingopraphy: a text and atlas. Baltimore: Urban &amp; Schwarzenberg, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24150/abstract/18\">",
"      Karande VC, Pratt DE, Balin MS, et al. What is the radiation exposure to patients during a gynecoradiologic procedure? Fertil Steril 1997; 67:401.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3262 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24150=[""].join("\n");
var outline_f23_37_24150=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIMING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Media",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATIENT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Contrast allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Technical problems and solutions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSTIC ACCURACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SIDE EFFECTS AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      POSTPROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3262\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3262|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/10/21664\" title=\"diagnostic image 1\">",
"      Normal HSG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/53/9040\" title=\"diagnostic image 2A\">",
"      HSG showing endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/63/23536\" title=\"diagnostic image 2B\">",
"      HSG showing submucous fibroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/29/43487\" title=\"diagnostic image 2C\">",
"      HSG showing synechiae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/5/27743\" title=\"diagnostic image 3\">",
"      HSG oblique view fibroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/42/41633\" title=\"diagnostic image 4\">",
"      HSG hydrosalpinx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/0/11264\" title=\"diagnostic image 5\">",
"      HSG air bubbles in uterus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/18/19759\" title=\"diagnostic image 6\">",
"      HSG with traction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/13/13520\" title=\"diagnostic image 7\">",
"      HSG arcuate ut intravasation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3262|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/54/35695\" title=\"picture 1\">",
"      HSG with air bubble artifact",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=related_link\">",
"      Causes of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26679?source=related_link\">",
"      Evaluation of couples with recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=related_link\">",
"      Saline infusion sonohysterography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_37_24151="Parastomal hernia";
var content_f23_37_24151=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parastomal hernia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/37/24151/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/37/24151/contributors\">",
"     Robert R Cima, MD, MA, FACS, FASCRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/37/24151/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/37/24151/contributors\">",
"     Richard Turnage, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/37/24151/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/37/24151/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/37/24151/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 21, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A parastomal hernia (PSH) is a type of incisional hernia that occurs at the site of the stoma or immediately adjacent to the stoma. It forms when the abdominal wall defect, the trephine, is continually stretched by the tangential forces applied along the circumference of the abdominal wall opening [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The construction of an ostomy and the management of patients with an ileostomy or colostomy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=see_link\">",
"     \"Surgical principles of ostomy construction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link\">",
"     \"Management of patients with a colostomy or ileostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A PSH is the most frequent complication following the construction of a colostomy or an ileostomy. It has even been suggested that a certain degree of PSH is almost inevitable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported incidence varies widely and is related to a number of factors including: the lack of a standard definition, type of ostomy constructed, and variability in the duration of follow-up after ostomy construction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/3-13\">",
"     3-13",
"    </a>",
"    ]. A minor degree of parastomal weakness is present in many patients and does not represent a true hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A literature review found that PSH occurs in 1.8 to 28.3 percent of patients with end ileostomies, 0 to 6.2 percent with loop ileostomies, 4.0 to 48.1 percent with end colostomies, and 0 to 30.8 percent with loop colostomies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/15\">",
"     15",
"    </a>",
"    ]. The lower rates for loop ostomies are related to the temporary nature of most of these stomas and the short duration of follow-up. Most parastomal hernias occur within the first two years from construction, and studies with longer follow-up have reported higher PSH rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hernia sac may contain bowel",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    omentum. PSH is classified clinically into four subtypes (",
"    <a class=\"graphic graphic_figure graphicRef69519 \" href=\"UTD.htm?42/48/43778\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subcutaneous (most common type) - The herniation extrudes from the abdomen alongside the bowel for the stoma and bulges into the subcutaneous fat alongside the stoma.",
"     </li>",
"     <li>",
"      Interstitial - The herniation extrudes alongside the bowel for the stoma, then burrows into one of the intermuscular planes.",
"     </li>",
"     <li>",
"      Perstomal - The stomal bowel is prolapsed and loops of bowel",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      omentum enter the hernia space produced between the layers of the prolapsed bowel.",
"     </li>",
"     <li>",
"      Intrastomal - The herniation extrudes from the abdomen alongside the bowel for the stoma and enters the plane between the emerging and the everted part of the bowel. It usually occurs in the spout type of stoma such as an ileostomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A radiologic classification scheme using findings from cross sectional imaging has also been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/17\">",
"     17",
"    </a>",
"    ]. This scheme distinguishes between possible contents of the hernia sac, including omentum, the loop of bowel forming the ostomy, and other loops of bowel not forming the ostomy.",
"   </p>",
"   <p>",
"    While these classification schemes may be useful in research and for academic discussions, in practice there is little need for such a system since management is based on the symptoms induced by the hernia, rather than differences in the hernia composition, which may be difficult to appreciate on physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient characteristics that have been associated with an increased risk of PSH formation include obesity, weight gain after ostomy construction, poor nutritional status, immunosuppressive drugs (eg, corticosteroids), emergency construction of a stoma, chronic or recurrent increases in abdominal pressure (chronic coughing), infection, and underlying disease such as malignancy or inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. Of these, the association with obesity, defined as waist circumference &gt;100 cm or body mass index &gt;30",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    is best supported by clinical evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/7,22\">",
"     7,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Technical factors that might influence the risk of PSH formation include stoma placement, surgical technique for ostomy construction, and abdominal wall strength [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The size of the trephine may be particularly important. An analysis of the forces acting upon the trephine that cause dilatation, thus a hernia, revealed that the larger the trephine radius, the stronger the tangential force pulling the trephine apart [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/1\">",
"     1",
"    </a>",
"    ]. This physical analysis supports the clinical findings that PSH is less common following an ileostomy than a colostomy or end stoma as compared to a loop stoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also increasing evidence that herniation in general is the result of an intrinsic defect in collagen metabolism and wound repair [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Hence, prosthetic mesh has been introduced to minimize tension on fascia in hernia repairs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65241097\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of parastomal hernia (PSH) after construction on an ostomy has, in different studies and different techniques, occurred in 0 to 48 percent of patients. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Incidence'",
"    </a>",
"    above.) In an attempt to reduce the rate of PSH, the current focus is on modifying risk factors for PSH formation prior to surgery and on better primary stomal construction techniques to strengthen the abdominal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/28-36\">",
"     28-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best available data on prevention of PSH comes from a randomized trial in which 54 patients who required a colostomy following an abdominal perineal resection; the patients were assigned to an ostomy construction with or without mesh in the sublay position (",
"    <a class=\"graphic graphic_figure graphicRef82341 \" href=\"UTD.htm?39/17/40210\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Intraabdominal repair with mesh'",
"    </a>",
"    below.)&nbsp;There were significantly fewer parastomal hernias in the mesh group (15 versus 41 percent) with no difference in complication rates. There were no episodes of mesh intolerance or mesh removal during the two year follow-up period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with a PSH are asymptomatic and do not require surgical repair. They typically present with a bulge at the site of or adjacent to the intestinal stoma, with or without pain (",
"    <a class=\"graphic graphic_picture graphicRef76715 \" href=\"UTD.htm?40/47/41712\">",
"     picture 1",
"    </a>",
"    ). Symptoms range from mild abdominal discomfort, back pain, intermittent cramping, distention, nausea, vomiting, diarrhea, constipation, and a reducible hernia, to severe abdominal pain, fever, and an unreducible hernia, which can be signs of a life-threatening complication. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Complications requiring surgical intervention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis is based on characteristic findings of a parastomal hernia on physical examination. After removal of the appliance, the patient is examined in the standing position and asked to perform the Valsalva maneuver. A hernia and the paracolostomy or paraileostomy tissue can be identified by digital exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/15,28\">",
"     15,28",
"    </a>",
"    ]. Diagnostic imaging to evaluate subclinical PSH in patients with a negative physical examination is unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPLICATIONS REQUIRING SURGICAL INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a low rate of life threatening complications associated with PSH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/14,15,37,38\">",
"     14,15,37,38",
"    </a>",
"    ]. Urgent or emergent surgical repair because of the risk of ischemic bowel is necessary for patients with a high grade obstruction resulting from strangulation or an unreducible hernia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=see_link&amp;anchor=H13#H13\">",
"     \"Small bowel obstruction: Causes and management\", section on 'Initial management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with the following signs or symptoms can be repaired electively:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing PSH size",
"     </li>",
"     <li>",
"      Peristomal skin breakdown",
"     </li>",
"     <li>",
"      Intermittent bowel obstructions",
"     </li>",
"     <li>",
"      Stoma appliance dysfunction and leakage",
"     </li>",
"     <li>",
"      Chronic back",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abdominal pain related to the PSH",
"     </li>",
"     <li>",
"      Psychological distress caused by any of the previous symptoms",
"     </li>",
"     <li>",
"      Stoma dysfunction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link&amp;anchor=H24#H24\">",
"       \"Management of patients with a colostomy or ileostomy\", section on 'Complications'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NONSURGICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical repair is avoided in most patients with no or mild symptoms because of the high recurrence rates. While no randomized trial has been conducted, most patients with mild symptoms can be managed with an ostomy hernia belt [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These patients should be educated about signs and symptoms of obstruction, strangulation, and infarction of bowel and instructed to contact the surgeon's office promptly if these symptoms occur. Delays in diagnosis of ischemic bowel can be life-threatening and may result in severe electrolyte imbalance, sepsis, and death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SURGICAL REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The techniques for repair of PSH include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relocation of the stoma",
"     </li>",
"     <li>",
"      Direct repair of the fascial defect",
"     </li>",
"     <li>",
"      Repair using a prosthetic mesh",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A multitude of different approaches has been reported; there is no ideal repair and all are associated with varying recurrence rates. Complicating the assessment and comparison of the success of the different repair techniques is that most can be performed using various standard surgical procedures, including a local open repair at the stoma site, laparotomy, or a laparoscopic approach (",
"    <a class=\"graphic graphic_figure graphicRef67797 \" href=\"UTD.htm?17/8/17542\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Repair using prosthetic mesh",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high local failure rate of direct fascial repair for incisional, inguinal, and parastomal hernias and the evidence for defects in collagen metabolism (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above) led to the development of local repairs with prosthetic mesh, which is the most common method of PSH repair (",
"    <a class=\"graphic graphic_figure graphicRef60131 \" href=\"UTD.htm?3/40/3714\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The overall success rate for a repair with mesh is relatively high compared with repair without mesh, although all of the reports are nonrandomized, include small patient numbers, use different techniques, and have variable follow-up. However, a mesh repair is still associated with a local failure rate of 4 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/39-47\">",
"     39-47",
"    </a>",
"    ]. Furthermore, complications such as contamination of the mesh and fistula formation, while very rare, can be devastating [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Direct fascial repair with mesh",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this technique, an incision is made in the abdominal wall well away from the stoma and a subcutaneous dissection along the rectus and oblique fascia is performed circumferentially around the stoma. The content of the hernia is reduced into the abdomen and abdominal wall defect is closed using a tension free mesh repair. While all of the series describing this technique are small, nonrandomized, and lack long-term follow-up, these reports describe low complication rates and recurrence rates of 0 to 20 percent. The use of closed suction drains overlying the mesh appears to reduce complications resulting from seroma collections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the use of drains to minimize the risk associated with seroma formation needs to be balanced against the possible risk of mesh infection.",
"   </p>",
"   <p>",
"    The advantages of a direct fascial repair are: (1) that it avoids the need for a formal laparotomy and (2) it does not require relocation of the stoma. A disadvantage is that undermining the skin around the stoma risks ischemic injury to the skin, which can result in significant management problems with the stoma appliance. Furthermore, the risk of infection contaminating the mesh is higher than intraperitoneal placement of mesh.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Intraabdominal repair with mesh",
"    </span>",
"    &nbsp;&mdash;&nbsp;By far the most common approach to PSH repair is an intra-abdominal repair with a prosthetic mesh. The mesh may be placed above the fascia (onlay technique) or below the fascia and muscular layers (preperitoneal or sublay technique) (",
"    <a class=\"graphic graphic_figure graphicRef82149 \" href=\"UTD.htm?25/42/26275\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/25,41,44,48-59\">",
"     25,41,44,48-59",
"    </a>",
"    ]. Insertion of mesh into the abdominal wall defect (inlay technique) has been abandoned because of high failure rates.",
"   </p>",
"   <p>",
"    The technique for mesh repair is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of abdominal hernias\", section on 'Mesh repair'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onlay technique has the advantage of being technically a more straight forward repair and avoids a large intra-abdominal dissection. It is associated with a higher risk of contamination and sepsis than the sublay technique. The sublay technique has a higher risk of adhesions and intestinal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/41,49\">",
"     41,49",
"    </a>",
"    ]. Identifying the best suited material for the mesh and establishing the best site for the placement of the mesh are the main problems with this technique. Similar to the surgical experience with incisional hernia repairs, the sublay technique is associated with fewer recurrences because intra-abdominal pressure does not dislocate the mesh from the repair [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several variations on the technique to place the mesh. The common aspect of all of the approaches is the reduction of the hernia contents into the abdominal cavity and closure of the defect by securing a piece of mesh under the defect with wide overlap onto the normal abdominal wall. The loop of bowel forming the ostomy is either brought out directly through a defect in the mesh, the \"key hole\" technique, or around the mesh, similar to the extraperitoneal ostomy construction. The bowel loop exiting at the stoma site is secured to the lateral and anterior abdominal wall and then a large piece of mesh is attached to the anterior and lateral abdominal wall over this loop of bowel, excluding all other bowel loops from contacting or protruding through the abdominal wall at the trephine for the stoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Laparoscopic mesh repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of decreased patient morbidity and improved outcomes with laparoscopic tension-free mesh repair of ventral and incisional hernias have led surgeons to apply these techniques to the repair of PSH. The Sugarbaker technique and modifications thereof have been widely used in laparoscopic repairs since it avoids the need for making apertures in the mesh, which make laparoscopic placement more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/55,57\">",
"     55,57",
"    </a>",
"    ]. Short-term results are promising (recurrence rate less than 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/25,61\">",
"     25,61",
"    </a>",
"    ], but longer term results (more than 24 months) are not available (",
"    <a class=\"graphic graphic_figure graphicRef82341 \" href=\"UTD.htm?39/17/40210\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is very little data to determine which patients with PSH are best treated via a laparoscopic approach or an open approach. Based upon the experience with midline incisional hernias, a laparoscopic approach is best offered in patient with a smaller (&lt;8 to 12 cm) hernia. Laparoscopic repair is also best reserved for when the surgeon does not anticipate extensive intestinal adhesions or extensive anterior peritoneal wall scarring from prior surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Biologic substitutes for prosthetic mesh",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most recent approach for PSH repair is use of biologic tissue instead of prosthetic mesh [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/43,63-66\">",
"     43,63-66",
"    </a>",
"    ]. The theoretical advantage is that it avoids the placement of synthetic material near the bowel and near a highly contaminated site, the stoma; however, biologic materials can cost thousands of dollars per piece. A review of four retrospective studies that included 57 patients with a PSH repaired with a biologic graft found a recurrence rate of 16 percent and wound complication rate of 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/67\">",
"     67",
"    </a>",
"    ]. This is comparable to the failure rate of PSH repair using prosthetic mesh. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Repair using prosthetic mesh'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    While the data are limited regarding the use of biologic tissue substitutes for PSH, it should be considered in patients who are at especially high risk for synthetic mesh complications, such as inflammatory bowel disease patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Relocation of the stoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the most common approach to a symptomatic PSH was to relocate the stoma to another site on the abdominal wall. This approach is to be generally avoided because the construction of a new stoma at a new site is associated with the same high risk of hernia formation as the primary stoma operation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/39,68\">",
"     39,68",
"    </a>",
"    ]. The local recurrence rate is approximately 36 percent (range 0 to 76 percent) and complication rates are as high as 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/38,39,47,68\">",
"     38,39,47,68",
"    </a>",
"    ]. This wide range of recurrence and complication rates reflects the variations of the definition of a PSH, type of stoma, size of defect, indications for a repair, length of time of follow-up, and whether or not the PSH is symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Direct repair of the fascial defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;To address the high recurrence rate with relocation of a stoma, surgeons performed direct repairs of the hernia similar to suture repairs of inguinal and incisional hernias. A direct fascial repair involves reducing the size of the hernia defect by reapproximating the fascial edges of the trephine with permanent sutures. A direct local repair involves a dissection of the fascia at the site of the stoma. This approach can be performed at the local site externally or via a laparotomy incision or laparoscopically.",
"   </p>",
"   <p>",
"    This approach is also generally avoided because the physics of PSH and the nature of the defect are not amenable to this simplistic approach. Another problem with this repair is that it violates an important surgical tenet of successful tissue healing: no tension should be placed on the repair. Recurrence rates for a primary fascial repair are high, ranging from 30 to 76 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24151/abstract/39,68,69\">",
"     39,68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A parastomal hernia (PSH) is a type of incisional hernia that occurs at the site of the stoma or immediately adjacent to the stoma. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of a PSH is an almost inevitable complication following the construction of an intestinal stoma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obesity defined as a waist circumference of &gt;100 centimeters is associated with a high risk of PSH. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using prosthetic mesh for construction of a permanent colostomy to reduce the risk of PSH formation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H65241097\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with a PSH are asymptomatic. Symptoms range from mild abdominal discomfort to life-threatening symptoms. Patients typically present with a bulge at the site of or adjacent to the intestinal stoma, with or without pain (",
"      <a class=\"graphic graphic_picture graphicRef76715 \" href=\"UTD.htm?40/47/41712\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis is based on characteristic findings of a hernia on physical examination. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that most patients with a parastomal hernia be initially managed with nonsurgical conservative management, such as using an ostomy hernia belt (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Nonsurgical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with signs and symptoms of ischemic bowel undergo an urgent or emergent surgical repair. (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complications requiring surgical intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using prosthetic mesh for the repair of the PSH (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The mesh can be inserted laparoscopically or via a laparotomy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Surgical repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that the repair be performed laparoscopically in patients with a hernia less than 8 to 12 centimeters and when there is no pre-operative evidence of extensive intra-abdominal adhesions (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients not meeting these criteria, we suggest that the repair be performed via laparotomy. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Surgical repair'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/1\">",
"      de Ruiter P, Bijnen AB. Successful local repair of paracolostomy hernia with a newly developed prosthetic device. Int J Colorectal Dis 1992; 7:132.",
"     </a>",
"    </li>",
"    <li>",
"     Goligher, J. Surgery of the Anus, Colon and Rectum, 5th ed, Balleire Tindall, London 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/3\">",
"      Whittaker M, Goligher JC. A comparison of the results of extraperitoneal and intraperitoneal techniques for construction of terminal iliac colostomies. Dis Colon Rectum 1976; 19:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/4\">",
"      Cheung MT. Complications of an abdominal stoma: an analysis of 322 stomas. Aust N Z J Surg 1995; 65:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/5\">",
"      M&auml;kel&auml; JT, Turku PH, Laitinen ST. Analysis of late stomal complications following ostomy surgery. Ann Chir Gynaecol 1997; 86:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/6\">",
"      Leenen LP, Kuypers JH. Some factors influencing the outcome of stoma surgery. Dis Colon Rectum 1989; 32:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/7\">",
"      Arumugam PJ, Bevan L, Macdonald L, et al. A prospective audit of stomas--analysis of risk factors and complications and their management. Colorectal Dis 2003; 5:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/8\">",
"      Leong AP, Londono-Schimmer EE, Phillips RK. Life-table analysis of stomal complications following ileostomy. Br J Surg 1994; 81:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/9\">",
"      Porter JA, Salvati EP, Rubin RJ, Eisenstat TE. Complications of colostomies. Dis Colon Rectum 1989; 32:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/10\">",
"      Harshaw DH Jr, Gardner B, Vives A, Sundaram KN. The effect of technical factors upon complications from abdominal perineal resections. Surg Gynecol Obstet 1974; 139:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/11\">",
"      Marks CG, Ritchie JK. The complications of synchronous combined excision for adenocarcinoma of the rectum at St Mark's Hospital. Br J Surg 1975; 62:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/12\">",
"      von Smitten K, Husa A, Kyll&ouml;nen L. Long-term results of sigmoidostomy in patients with anorectal malignancy. Acta Chir Scand 1986; 152:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/13\">",
"      Kronborg O, Kramh&ouml;ft J, Backer O, Sprechler M. Late complications following operations for cancer of the rectum and anus. Dis Colon Rectum 1974; 17:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/14\">",
"      Martin L, Foster G. Parastomal hernia. Ann R Coll Surg Engl 1996; 78:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/15\">",
"      Carne PW, Robertson GM, Frizelle FA. Parastomal hernia. Br J Surg 2003; 90:784.",
"     </a>",
"    </li>",
"    <li>",
"     Devlin HB. Peristomal hernia. In: Operative Surgery Volume 1: Alimentary Tract and Abdominal Wall, 4th ed, Dudley H (Ed), Butterworths, London 1983. p.441.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/17\">",
"      Moreno-Matias J, Serra-Aracil X, Darnell-Martin A, et al. The prevalence of parastomal hernia after formation of an end colostomy. A new clinico-radiological classification. Colorectal Dis 2009; 11:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/18\">",
"      Pearl RK. Parastomal hernias. World J Surg 1989; 13:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/19\">",
"      Leslie D. The parastomal hernia. Surg Clin North Am 1984; 64:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/20\">",
"      Rosin JD, Bonardi RA. Paracolostomy hernia repair with Marlex mesh: a new technique. Dis Colon Rectum 1977; 20:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/21\">",
"      Bass EM, Del Pino A, Tan A, et al. Does preoperative stoma marking and education by the enterostomal therapist affect outcome? Dis Colon Rectum 1997; 40:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/22\">",
"      De Raet J, Delvaux G, Haentjens P, Van Nieuwenhove Y. Waist circumference is an independent risk factor for the development of parastomal hernia after permanent colostomy. Dis Colon Rectum 2008; 51:1806.",
"     </a>",
"    </li>",
"    <li>",
"     Colwell JC. Stomal and peristomal complications. In: Fecal &amp; Urinary Diversions: Management Principles, Goldberg MT, Colwell JC, Carmel JE (Eds), Mosby, St. Louis 2004. p.308.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/24\">",
"      Trunbull GB. Parastomal hernias. Ostomy Wound Manage 2003; 49:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/25\">",
"      Hansson BM, de Hingh IH, Bleichrodt RP. Laparoscopic parastomal hernia repair is feasible and safe: early results of a prospective clinical study including 55 consecutive patients. Surg Endosc 2007; 21:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/26\">",
"      Junge K, Klinge U, Rosch R, et al. Decreased collagen type I/III ratio in patients with recurring hernia after implantation of alloplastic prostheses. Langenbecks Arch Surg 2004; 389:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/27\">",
"      Rosch R, Junge K, Knops M, et al. Analysis of collagen-interacting proteins in patients with incisional hernias. Langenbecks Arch Surg 2003; 387:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/28\">",
"      Serra-Aracil X, Bombardo-Junca J, Moreno-Matias J, et al. Randomized, controlled, prospective trial of the use of a mesh to prevent parastomal hernia. Ann Surg 2009; 249:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/29\">",
"      Helgstrand F, G&ouml;genur I, Rosenberg J. Prevention of parastomal hernia by the placement of a mesh at the primary operation. Hernia 2008; 12:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/30\">",
"      J&auml;nes A, Cengiz Y, Israelsson LA. Preventing parastomal hernia with a prosthetic mesh: a 5-year follow-up of a randomized study. World J Surg 2009; 33:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/31\">",
"      Vijayasekar C, Marimuthu K, Jadhav V, Mathew G. Parastomal hernia: Is prevention better than cure? Use of preperitoneal polypropylene mesh at the time of stoma formation. Tech Coloproctol 2008; 12:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/32\">",
"      J&auml;nes A, Cengiz Y, Israelsson LA. Randomized clinical trial of the use of a prosthetic mesh to prevent parastomal hernia. Br J Surg 2004; 91:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/33\">",
"      Israelsson LA. Preventing and treating parastomal hernia. World J Surg 2005; 29:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/34\">",
"      Marimuthu K, Vijayasekar C, Ghosh D, Mathew G. Prevention of parastomal hernia using preperitoneal mesh: a prospective observational study. Colorectal Dis 2006; 8:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/35\">",
"      G&ouml;genur I, Mortensen J, Harvald T, et al. Prevention of parastomal hernia by placement of a polypropylene mesh at the primary operation. Dis Colon Rectum 2006; 49:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/36\">",
"      Geisler DJ, Reilly JC, Vaughan SG, et al. Safety and outcome of use of nonabsorbable mesh for repair of fascial defects in the presence of open bowel. Dis Colon Rectum 2003; 46:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/37\">",
"      Sj&ouml;dahl R, Anderberg B, Bolin T. Parastomal hernia in relation to site of the abdominal stoma. Br J Surg 1988; 75:339.",
"     </a>",
"    </li>",
"    <li>",
"     Harold, KL. Laparoscopic parastomal hernia repair. In: Challenging Hernias PostGraduate Course. SAGES Annual Meeting. Philadelphia, PA, April 2008. p. 43.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/39\">",
"      Rubin MS, Schoetz DJ Jr, Matthews JB. Parastomal hernia. Is stoma relocation superior to fascial repair? Arch Surg 1994; 129:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/40\">",
"      Franks ME, Hrebinko RL Jr. Technique of parastomal hernia repair using synthetic mesh. Urology 2001; 57:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/41\">",
"      Byers JM, Steinberg JB, Postier RG. Repair of parastomal hernias using polypropylene mesh. Arch Surg 1992; 127:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/42\">",
"      Morris-Stiff G, Hughes LE. The continuing challenge of parastomal hernia: failure of a novel polypropylene mesh repair. Ann R Coll Surg Engl 1998; 80:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/43\">",
"      Aldridge AJ, Simson JN. Erosion and perforation of colon by synthetic mesh in a recurrent paracolostomy hernia. Hernia 2001; 5:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/44\">",
"      Kasperk R, Klinge U, Schumpelick V. The repair of large parastomal hernias using a midline approach and a prosthetic mesh in the sublay position. Am J Surg 2000; 179:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/45\">",
"      Schumpelick V, Klinge U, Welty G, Klosterhalfen B. [Meshes within the abdominal wall]. Chirurg 1999; 70:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/46\">",
"      Steele SR, Lee P, Martin MJ, et al. Is parastomal hernia repair with polypropylene mesh safe? Am J Surg 2003; 185:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/47\">",
"      Tekkis PP, Kocher HM, Payne JG. Parastomal hernia repair: modified thorlakson technique, reinforced by polypropylene mesh. Dis Colon Rectum 1999; 42:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/48\">",
"      Stelzner S, Hellmich G, Ludwig K. Repair of paracolostomy hernias with a prosthetic mesh in the intraperitoneal onlay position: modified Sugarbaker technique. Dis Colon Rectum 2004; 47:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/49\">",
"      Sugarbaker PH. Peritoneal approach to prosthetic mesh repair of paraostomy hernias. Ann Surg 1985; 201:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/50\">",
"      van Sprundel TC, Gerritsen van der Hoop A. Modified technique for parastomal hernia repair in patients with intractable stoma-care problems. Colorectal Dis 2005; 7:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/51\">",
"      Guzm&aacute;n-Valdivia G, Guerrero TS, Laurrabaquio HV. Parastomal hernia-repair using mesh and an open technique. World J Surg 2008; 32:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/52\">",
"      Baig MK, Larach JA, Chang S, et al. Outcome of parastomal hernia repair with and without midline laparotomy. Tech Coloproctol 2006; 10:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/53\">",
"      LeBlanc KA, Bellanger DE. Laparoscopic repair of paraostomy hernias: early results. J Am Coll Surg 2002; 194:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/54\">",
"      Virz&iacute; G, Giuseppe V, Scaravilli F, et al. Laparoscopic paracolostomy hernia mesh repair. Surg Laparosc Endosc Percutan Tech 2007; 17:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/55\">",
"      Berger D, Bientzle M. Laparoscopic repair of parastomal hernias: a single surgeon's experience in 66 patients. Dis Colon Rectum 2007; 50:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/56\">",
"      Jani K, Palanivelu C, Parthasarathi R, Madhankumar MV. Laparoscopic repair of a paracolostomy hernia: secure reinforced closure of the defect prevents recurrence. J Laparoendosc Adv Surg Tech A 2007; 17:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/57\">",
"      Mancini GJ, McClusky DA 3rd, Khaitan L, et al. Laparoscopic parastomal hernia repair using a nonslit mesh technique. Surg Endosc 2007; 21:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/58\">",
"      Voitk A. Simple technique for laparoscopic paracolostomy hernia repair. Dis Colon Rectum 2000; 43:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/59\">",
"      Muysoms EE, Hauters PJ, Van Nieuwenhove Y, et al. Laparoscopic repair of parastomal hernias: a multi-centre retrospective review and shift in technique. Acta Chir Belg 2008; 108:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/60\">",
"      Cassar K, Munro A. Surgical treatment of incisional hernia. Br J Surg 2002; 89:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/61\">",
"      Berger D, Bientzle M. Polyvinylidene fluoride: a suitable mesh material for laparoscopic incisional and parastomal hernia repair! A prospective, observational study with 344 patients. Hernia 2009; 13:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/62\">",
"      Rosen MJ, Fatima J, Sarr MG. Repair of abdominal wall hernias with restoration of abdominal wall function. J Gastrointest Surg 2010; 14:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/63\">",
"      Kish KJ, Buinewicz BR, Morris JB. Acellular dermal matrix (AlloDerm): new material in the repair of stoma site hernias. Am Surg 2005; 71:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/64\">",
"      Greenstein AJ, Aldoroty RA. Parastomal hernia repair using cross-linked porcine dermis: report of a case. Surg Today 2008; 38:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/65\">",
"      Lo Menzo E, Martinez JM, Spector SA, et al. Use of biologic mesh for a complicated paracolostomy hernia. Am J Surg 2008; 196:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/66\">",
"      Taner T, Cima RR, Larson DW, et al. The use of human acellular dermal matrix for parastomal hernia repair in patients with inflammatory bowel disease: a novel technique to repair fascial defects. Dis Colon Rectum 2009; 52:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/67\">",
"      Slater NJ, Hansson BM, Buyne OR, et al. Repair of parastomal hernias with biologic grafts: a systematic review. J Gastrointest Surg 2011; 15:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/68\">",
"      Cheung MT, Chia NH, Chiu WY. Surgical treatment of parastomal hernia complicating sigmoid colostomies. Dis Colon Rectum 2001; 44:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24151/abstract/69\">",
"      Horgan K, Hughes LE. Para-ileostomy hernia: failure of a local repair technique. Br J Surg 1986; 73:439.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3691 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24151=[""].join("\n");
var outline_f23_37_24151=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H65241097\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPLICATIONS REQUIRING SURGICAL INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NONSURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SURGICAL REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Repair using prosthetic mesh",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Direct fascial repair with mesh",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Intraabdominal repair with mesh",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Laparoscopic mesh repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Biologic substitutes for prosthetic mesh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Relocation of the stoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Direct repair of the fascial defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/3691\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3691|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/48/43778\" title=\"figure 1\">",
"      Types of parastomal hernias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/17/40210\" title=\"figure 2\">",
"      Abdominal wall mesh placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/8/17542\" title=\"figure 3\">",
"      Surgical repair of parastomal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/40/3714\" title=\"figure 4\">",
"      Mesh repair of parastomal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/42/26275\" title=\"figure 5\">",
"      Laparoscopic mesh repair of parastomal hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3691|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/47/41712\" title=\"picture 1\">",
"      Parastomal hernia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=related_link\">",
"      Small bowel obstruction: Causes and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=related_link\">",
"      Surgical principles of ostomy construction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_37_24152="Ramipril: Drug information";
var content_f23_37_24152=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ramipril: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/12/23749?source=see_link\">",
"    see \"Ramipril: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Altace&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Altace&reg;;",
"     </li>",
"     <li>",
"      Apo-Ramipril&reg;;",
"     </li>",
"     <li>",
"      Ava-Ramipril;",
"     </li>",
"     <li>",
"      CO Ramipril;",
"     </li>",
"     <li>",
"      Dom-Ramipril;",
"     </li>",
"     <li>",
"      JAMP-Ramipril;",
"     </li>",
"     <li>",
"      Mylan-Ramipril;",
"     </li>",
"     <li>",
"      PHL-Ramipril;",
"     </li>",
"     <li>",
"      PMS-Ramipril;",
"     </li>",
"     <li>",
"      RAN&trade;-Ramipril;",
"     </li>",
"     <li>",
"      ratio-Ramipril;",
"     </li>",
"     <li>",
"      Sandoz-Ramipril;",
"     </li>",
"     <li>",
"      Teva-Ramipril",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F217209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F217170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure (unlabeled use):",
"     </b>",
"     Initial: 1.25-2.5 mg once daily; target dose: 10 mg once daily (ACC/AHA 2009 Heart Failure Guidelines)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 2.5-5 mg once daily, maximum: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      LV dysfunction postmyocardial infarction:",
"     </b>",
"     Oral: Initial: 2.5 mg twice daily titrated upward, if possible, to 5 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      To reduce the risk of MI, stroke, and death from cardiovascular causes:",
"     </b>",
"     Oral: Initial: 2.5 mg once daily for 1 week, then 5 mg once daily for the next 3 weeks, then increase as tolerated to 10 mg once daily (may be given as divided dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The dose of any concomitant diuretic should be reduced. If the diuretic cannot be discontinued, initiate therapy with 1.25 mg. After the initial dose, the patient should be monitored carefully until blood pressure has stabilized.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F217171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Adjust for renal function for elderly since glomerular filtration rates are decreased; may see exaggerated hypotensive effects if renal clearance is not considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     In the management of hypertension, consider lower initial doses and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F217172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute: Administer 25% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal failure and heart failure: Administer 1.25 mg once daily, increasing to 1.25 mg twice daily up to 2.5 mg twice daily as tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal failure and hypertension: Administer 1.25 mg once daily, titrated upward as possible; maximum daily dose 5 mg.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 1.25 mg, 2.5 mg, 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altace&reg;: 1.25 mg, 2.5 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F217142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsule is usually swallowed whole, but contents may be mixed in water, apple juice, or applesauce.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F217141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, alone or in combination with thiazide diuretics; treatment of left ventricular dysfunction after MI; to reduce risk of MI, stroke, and death in patients at increased risk for these events",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F1670661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of heart failure; to delay the progression of nephropathy and reduce risks of cardiovascular events in hypertensive patients with type 1 or 2 diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F217217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ramipril may be confused with enalapril, Monopril&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Altace&reg; may be confused with Altace&reg; HCT, alteplase, Amaryl&reg;, Amerge&reg;, Artane",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F217207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequency ranges include data from hypertension and heart failure trials. Higher rates of adverse reactions have generally been noted in patients with CHF. However, the frequency of adverse effects associated with placebo is also increased in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%: Respiratory: Cough increased (7% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (11%), angina (up to 3%), orthostatic hypotension (2%), syncope (up to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1% to 5%), dizziness (2% to 4%), fatigue (2%), vertigo (up to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (1% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chest pain (noncardiac) (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal dysfunction (1%), serum creatinine increased (1% to 2%), BUN increased (&lt;1% to 3%); transient increases of creatinine and/or BUN may occur more frequently",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (estimated 1% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, amnesia, anaphylactoid reaction, angioedema, arrhythmia, bone marrow depression, convulsions, depression, dysphagia, eosinophilia, erythema multiforme, hearing loss, hemolytic anemia, hepatitis, hypersensitivity reactions (urticaria, rash, fever), impotence, insomnia, MI, neuropathy, onycholysis, pancreatitis, pancytopenia, pemphigoid, pemphigus, photosensitivity, proteinuria, Stevens-Johnson syndrome, symptomatic hypotension, thrombocytopenia, toxic epidermal necrolysis, visual hallucinations (Doane, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Worsening of renal function may occur in patients with bilateral renal artery stenosis or in hypovolemia. In addition, a syndrome which may include fever, myalgia, arthralgia, interstitial nephritis, vasculitis, rash, eosinophilia and positive ANA, and elevated ESR has been reported with ACE inhibitors. Risk of pancreatitis and/or agranulocytosis may be increased in patients with collagen vascular disease or renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F217145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ramipril or any component of the formulation; prior hypersensitivity (including angioedema) to ACE inhibitors; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F217127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts.  Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal artery stenosis: Use ramipril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction; concurrent use with telmisartan is not recommended. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F217132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telmisartan: May increase the serum concentration of Ramipril. Concentrations of the active metabolite, ramiprilat, may also be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F217160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice (may worsen hypertension). Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F217148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Ramipril crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor in utero should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F217176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F217149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ramipril and its metabolites were not detected in breast milk following a single oral dose of 10 mg. It is not known if multiple doses will produce detectable levels. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F217147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Altace Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg (100): $275.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $325.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $341.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $399.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ramipril Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg (100): $153.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $180.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $189.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $221.72",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6179363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum creatinine and potassium; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F217150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acovil (ES);",
"     </li>",
"     <li>",
"      Altace (VE);",
"     </li>",
"     <li>",
"      Cardace (ID, IN);",
"     </li>",
"     <li>",
"      Corpril (TH);",
"     </li>",
"     <li>",
"      Delix (DE, TR);",
"     </li>",
"     <li>",
"      Hartil (RU);",
"     </li>",
"     <li>",
"      Heartprilprotect (KP);",
"     </li>",
"     <li>",
"      Hyperil (ID);",
"     </li>",
"     <li>",
"      Hypren (AT);",
"     </li>",
"     <li>",
"      Lostapres (AR);",
"     </li>",
"     <li>",
"      Naprix (BR);",
"     </li>",
"     <li>",
"      Piramil (EE);",
"     </li>",
"     <li>",
"      Pramace (SE);",
"     </li>",
"     <li>",
"      Prilace (AU);",
"     </li>",
"     <li>",
"      Quark (IT);",
"     </li>",
"     <li>",
"      Ramace (AU, BE, DK, FI, LU, MY, NZ, PH, SG);",
"     </li>",
"     <li>",
"      Ramey (TW);",
"     </li>",
"     <li>",
"      Ramily (TW);",
"     </li>",
"     <li>",
"      Ramipres (CN);",
"     </li>",
"     <li>",
"      Ramiprin (KP);",
"     </li>",
"     <li>",
"      Ramipro (PH);",
"     </li>",
"     <li>",
"      Ramitace (TW);",
"     </li>",
"     <li>",
"      Ramixal (ID);",
"     </li>",
"     <li>",
"      Rampil (ZA);",
"     </li>",
"     <li>",
"      Ramtace (TH);",
"     </li>",
"     <li>",
"      Redutens (ID);",
"     </li>",
"     <li>",
"      Sipo (TW);",
"     </li>",
"     <li>",
"      Syntace (TW);",
"     </li>",
"     <li>",
"      Triatec (BR, CH, CN, DK, FR, GR, IL, IT, NO, PT, SE);",
"     </li>",
"     <li>",
"      Triateckit (FR);",
"     </li>",
"     <li>",
"      Tripril (MY);",
"     </li>",
"     <li>",
"      Tritace (AR, AT, AU, BB, BE, BF, BG, BJ, BM, BS, BZ, CI, CL, CO, CR, CZ, DK, DO, EC, ET, GB, GH, GM, GN, GT, GY, HK, HN, HR, HU, IE, JM, KE, KP, LR, LU, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, NZ, PA, PH, PK, PL, PR, PY, SC, SD, SL, SN, SR, SV, TH, TN, TT, TW, TZ, UG, UY, ZM, ZW);",
"     </li>",
"     <li>",
"      Tryzan (AU);",
"     </li>",
"     <li>",
"      Unipril (IT);",
"     </li>",
"     <li>",
"      Vesdil (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F217126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ramipril is an ACE inhibitor which prevents the formation of angiotensin II from angiotensin I and exhibits pharmacologic effects that are similar to captopril. Ramipril must undergo enzymatic saponification by esterases in the liver to its biologically active metabolite, ramiprilat. The pharmacodynamic effects of ramipril result from the high-affinity, competitive, reversible binding of ramiprilat to angiotensin-converting enzyme, thus preventing the formation of the potent vasoconstrictor angiotensin II. This isomerized enzyme-inhibitor complex has a slow rate of dissociation, which results in high potency and a long duration of action; a CNS mechanism may also be involved in the hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F217144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed (50% to 60%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Plasma levels decline in a triphasic fashion; rapid decline is a distribution phase to peripheral compartment, plasma protein and tissue ACE (half-life: 2-4 hours); second phase is an apparent elimination phase representing the clearance of free ramiprilat (half-life: 9-18 hours); and final phase is the terminal elimination phase representing the equilibrium phase between tissue binding and dissociation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Ramipril: 73%; Ramiprilat: 56%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to the active form, ramiprilat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Ramipril: 28%; Ramiprilat: 44%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Ramiprilat: Effective: 13-17 hours; Terminal: &gt;50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Ramipril: ~1 hour; Ramiprilat: 2-4  hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60%) and feces (40%) as parent drug and metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doane J and Stults B, &ldquo;Visual Hallucinations Related to Angiotensin-Converting Enzyme Inhibitor Use: Case Reports and Review,&rdquo;",
"      <i>",
"       J Clin Hypertens (Greenwich)",
"      </i>",
"      , 2013 [epub ahead pf print].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Death From Cardiovascular Causes, Myocardial Infarction, and Stroke in High-Risk Patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effects of Ramipril on Cardiovascular and Microvascular Outcomes in People with Diabetes Mellitus: Results of the HOPE Study and MICRO-HOPE Substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000 355(9200):253-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/10675071/pubmed\" id=\"10675071\" target=\"_blank\">",
"        10675071",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, &ldquo;Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):782-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/13678872/pubmed\" id=\"13678872\" target=\"_blank\">",
"        13678872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al, &ldquo;Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(23):2312-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/10587334/pubmed\" id=\"10587334\" target=\"_blank\">",
"        10587334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, Greaves SC, Arnold JM, et al, &ldquo;Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction. The Healing and Early Afterload Reducing Therapy Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 95(12):2643-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/9193433/pubmed\" id=\"9193433\" target=\"_blank\">",
"        9193433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1893-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/14610160/pubmed\" id=\"14610160\" target=\"_blank\">",
"        14610160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, &ldquo;Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/37/24152/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9851 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.147-B9BF6B98CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24152=[""].join("\n");
var outline_f23_37_24152=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709397\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217165\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217166\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217209\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217170\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217171\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217172\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217138\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217123\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217142\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217141\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1670661\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217217\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217207\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217145\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217127\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299980\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217132\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217160\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217135\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217148\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217176\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217149\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217147\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6179363\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217150\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217126\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217144\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9851\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9851|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/12/23749?source=related_link\">",
"      Ramipril: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_37_24153="PTCL-NOS histology";
var content_f23_37_24153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Peripheral T-cell lymphoma, not otherwise specified histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymph node biopsy of a&nbsp;peripheral T cell lymphoma&nbsp;shows tumor cells with clear cytoplasm and pleomorphic nuclei. There are two high endothelial venules present in this field. Hematoxylin and eosin, 40x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24153=[""].join("\n");
var outline_f23_37_24153=null;
var title_f23_37_24154="Inflammation in renal insufficiency";
var content_f23_37_24154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inflammation in renal insufficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/37/24154/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/37/24154/contributors\">",
"     Csaba P Kovesdy, MD, FASN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/37/24154/contributors\">",
"     Joel D Kopple, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/37/24154/contributors\">",
"     Kamyar Kalantar-Zadeh, MD, MPH, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/37/24154/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/37/24154/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/37/24154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/37/24154/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/37/24154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent or chronic Inflammatory processes are common in individuals with chronic renal disease (CKD), including those with chronic renal failure (CRF) and especially end-stage renal disease (ESRD). This is due to many underlying factors, including the uremic milieu, elevated levels of circulating proinflammatory cytokines, oxidative stress, carbonyl stress, protein-energy wasting, enhanced incidence of infections (especially dialysis-access related) and others. Although the definition of inflammation is unclear in this setting, CRF-associated chronic inflammation, as assessed by increased C-reactive protein (CRP) levels above 5",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    over at least three months, has been reported in 30 to 60 percent of North American and European dialysis patients, with dialysis patients in Asian countries possibly having a lower prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acute phase response is a major pathophysiologic phenomenon that accompanies inflammation. With this reaction, normal homeostatic mechanisms are replaced by new set points that presumably contribute to defensive or adaptive capabilities.",
"   </p>",
"   <p>",
"    Acute phase proteins are defined as those proteins whose plasma concentrations increase (positive acute phase proteins), such as C-reactive protein (CRP), or decrease (negative acute phase proteins) such as albumin, during inflammatory states. Measurement of the levels of these proteins is frequently utilized to define the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    degree of inflammation in a given patient. A number of inflammatory markers have been studied in patients with CKD (",
"    <a class=\"graphic graphic_table graphicRef75907 \" href=\"UTD.htm?37/2/37933\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite its name, the \"acute\" phase response can persist over months to years and become chronic. In such states of chronic inflammation, positive acute phase proteins including CRP (normal range &lt;1",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    may be slightly but persistently increased, which can predispose to an increased risk of atherosclerotic cardiovascular disease (CRP 1 to 3",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/8\">",
"     8",
"    </a>",
"    ]. However, in many CKD patients, especially in maintenance dialysis patients, serum CRP levels are persistently between 5 and 50",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    although they may fluctuate widely [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/8\">",
"     8",
"    </a>",
"    ]. During acute and fulminant infections, such as acute osteomyelitis, serum CRP is usually above 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef67050 \" href=\"UTD.htm?5/29/5595\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among patients with CKD, the presence of an inflammatory state may also be closely related to accelerated atherogenesis, protein-energy malnutrition (PEM), and anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal insufficiency alone is reported to be a risk factor for atherosclerosis and cardiovascular diseases (CVD). This may be due in part to concurrent inflammation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"       \"Chronic kidney disease and coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increasing attention has focused upon inflammation as a possible cause of the wasting syndrome in end-stage renal disease as well as anemia refractory to epoetin therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis and consequences of inflammatory processes among patients with renal dysfunction will be discussed in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFLAMMATION AND KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A generalized increase in the inflammatory response in patients with decreased renal function may occur via the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased clearance of proinflammatory cytokines",
"     </li>",
"     <li>",
"      Volume overload, with endotoxinemia",
"     </li>",
"     <li>",
"      Oxidative and carbonyl stress",
"     </li>",
"     <li>",
"      Decreased levels of antioxidants",
"     </li>",
"     <li>",
"      Increased presence of comorbid conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Decreased clearance of proinflammatory cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deteriorating renal function may enhance overall inflammatory responses because of the decreased renal clearance of factors that are directly or indirectly involved in inflammation. As an example, the serum half-lives of proinflammatory cytokines, tumor necrosis factor alpha and interleukin-1, are greater in animals without renal function than those with renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, declining renal function may also affect the levels of additional inflammatory molecules, as serum C-reactive protein (CRP), interleukin-6 and hyaluronan levels, are inversely correlated with creatinine clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In addition, among ESRD patients with residual renal function, higher serum CRP concentrations are observed among those with relatively less native kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Increased production of cytokines may also be observed (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Oxidative and carbonyl stress'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=see_link\">",
"     \"Uremic toxins\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Volume overload, with endotoxinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular congestion due to fluid overload in patients with renal insufficiency may result in altered permeability of the gastrointestinal tract, thereby leading to accumulation of endotoxins such as lipopolysaccharides and bacteria. These processes may in turn stimulate monocytes and the increased release of proinflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Oxidative and carbonyl stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased production of cytokines due to oxidative stress is also observed among patients with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Oxidative stress, which occurs when there is excessive free-radical production or low antioxidant levels, could be an important condition for the development of endothelial dysfunction, inflammation, and atherogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .) Lower plasmalogen levels, an indicator of such stress, have been reported in malnourished and inflamed patients with CRF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With renal failure, molecules that are not cytokines may also accumulate and provoke an inflammatory response. As an example, advanced glycosylated end-products (AGE), which result from carbonyl stress, can clearly initiate inflammation in patients with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=see_link\">",
"     \"Uremic toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Decreased antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral intake or the level of some antioxidants is lower than normal in both CRF and ESRD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/28\">",
"     28",
"    </a>",
"    ]. An acute-phase response is also associated with decreased plasma levels of several antioxidants, such as serum vitamin C concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/21,29\">",
"     21,29",
"    </a>",
"    ]. Low serum vitamin C levels are in turn associated with increased cardiovascular morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequent occurrence of comorbid illnesses in renal patients enhances the hypercatabolic state and the development of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/31\">",
"     31",
"    </a>",
"    ], such as periodontal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/32\">",
"     32",
"    </a>",
"    ]. Even in the absence of overt clinical illness, an inflammatory process may be ongoing and associated with an acute phase response in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, an increased susceptibility to infections has been described in dialysis patients that may be partly due to uremia, old age, and comorbid conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systemic autoimmune condition (which may have resulted in kidney disease), genetic factors, an unrecognized persistent infection, periodontal diseases, and atherosclerosis may also underlie inflammation among patients with decreased renal function or end-stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     End-stage renal disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the previously mentioned causes that may underlie",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enhance ongoing inflammation in patients with CRF, the following conditions may chronically aggravate inflammatory processes in those undergoing maintenance hemodialysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure to dialysis tubing and dialysis membranes, particularly less biocompatible membranes (eg, cuprophane membranes) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=see_link\">",
"       \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Poor quality of dialysis water and back-filtration or back-diffusion of contaminants, resulting in possible exposure to endotoxins. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29190?source=see_link\">",
"       \"Contaminants in water used for hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of foreign bodies (such as polytetrafluoroethylene [PTFE] chronic access grafts) or an intravenous catheter, which may harbor chronic or recurrent latent infection via the formation of a biofilm [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors unique in peritoneal dialysis (PD) patients may also enhance chronic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodes of overt or latent peritonitis or PD-catheter related infections [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/6,42,44\">",
"       6,42,44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Constant exposure to PD solution, which may include bioincompatible substances or endotoxins [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/42,44\">",
"       42,44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Loss of residual renal function and fluid overload [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Presence of a failed kidney transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chronic inflammatory state has been noted in patients who return to dialysis after a failed kidney transplant, but in whom a transplant nephrectomy has not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/45\">",
"     45",
"    </a>",
"    ]. Symptoms and signs of inflammation may abate with kidney removal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41111?source=see_link\">",
"     \"Withdrawal of immunosuppression after renal transplant failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     GENERAL MARKERS OF INFLAMMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus approach to assess the degree of severity of inflammation in individuals with kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .) Routine monitoring of inflammatory markers in all ESRD or CKD patients is currently not recommended by most guidelines, although it may improve patient management. Periodic measurement of CRP or IL-6 to assess severity and frequency of inflammation is reasonable in select patients as part of an individualized workup prompted by specific clinical characteristics, such as protein-energy wasting.",
"   </p>",
"   <p>",
"    Several measures of general inflammation are used in both CRF and ESRD patients as well as in others [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/46-56\">",
"     46-56",
"    </a>",
"    ]. These include the following proteins:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum levels of positive acute phase reactants, such as serum C-reactive protein (CRP), ferritin, or fibrinogen, are commonly elevated during an acute episode of inflammation. There is increasing literature on elevated serum CRP and increased cardiovascular risk, a relationship that is independent of other coronary risk factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link\">",
"       \"C-reactive protein in cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=see_link\">",
"       \"Screening for cardiovascular risk with C-reactive protein\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum levels of negative acute phase reactants, such as albumin or transferrin, decrease during an inflammatory process [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. Many negative acute phase reactants are also traditionally utilized as nutritional markers, since their serum levels are decreased with a decline in nutritional status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since episodes of occult or overt inflammation may be chronic or recurrent, they have occasionally been referred to as representing a \"chronic\" acute phase response [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Such chronic inflammatory responses are associated with an elevation of serum acute phase proteins including CRP, erythrocyte sedimentation rate, serum amyloid A, and some proinflammatory cytokines including a variety of interleukins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20081?source=see_link\">",
"     \"Erythrocyte sedimentation rate in renal disease\"",
"    </a>",
"    .) Among the proinflammatory cytokines, interleukin-6 (IL-6) may have a central role in the pathophysiology of inflammation in patients with renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No consensus currently exists as to what threshold levels of inflammatory markers optimally distinguish non-inflamed versus inflamed patients with ESRD, as well as what exact markers should be measured. Based upon mean values",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    possible correlation with outcomes, several investigators have proposed different serum levels of various markers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/1,46,57-62\">",
"     1,46,57-62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a survival study of 91 hemodialysis patients, a serum CRP level &gt;5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (&gt;0.5",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      as measured by end-point nephelometry) was proposed as a sign of inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/1\">",
"       1",
"      </a>",
"      ]. This was derived from the observation that the mean CRP values among patients who were alive or had died at study end were originally 3.4 and 10.1",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      In a prospective report of 240 peritoneal dialysis patients with an initial median serum CRP level of 7",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      the CRP level was significantly higher among the 84 patients who experienced a cardiovascular event during the subsequent 41 months (27",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third series, the mean serum interleukin-6 (IL-6) concentrations among hemodialysis and peritoneal dialysis patients were 7.2 and 5.6",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/58\">",
"       58",
"      </a>",
"      ]. When levels were categorized by quartiles, the group with the highest initial level had the highest mortality, a finding observed in both hemodialysis and peritoneal dialysis patients.",
"     </li>",
"     <li>",
"      In a review of 230 hemodialysis patients and 28 non-dialytic controls, serum concentrations of interleukins 1, 2, 4, 5, 6, 12, and 13 as well as TNF-alpha were significantly increased in the dialysis group [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are some patients with ESRD in whom the measurement of such inflammatory markers may help guide clinical decision-making. The measurement of serum CRP and IL-6, for example, may help distinguish the relative contributions of inflammation and malnutrition to the development of hypoalbuminemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/11,63\">",
"     11,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the serum measurement of inflammatory markers may help determine whether the presence of hyperferritinemia in dialysis patients is due to iron overload or inflammation; this may be particularly helpful when the serum ferritin level is &gt;800",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    but the serum transferrin saturation is within the normal range (&lt;50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/64\">",
"     64",
"    </a>",
"    ]. The association between increased mortality and serum ferritin levels &gt;800",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    appears to be primarily due to the confounding effect of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28005?source=see_link\">",
"     \"Diagnosis of iron deficiency in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DOES INFLAMMATION LEAD TO MALNUTRITION?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein-energy malnutrition (PEM), also referred to as protein-energy wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/66\">",
"     66",
"    </a>",
"    ], which is present in a large proportion of patients with ESRD, is a strong risk factor for increased hospitalization and mortality in patients undergoing maintenance hemodialysis or peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/11,49,67\">",
"     11,49,67",
"    </a>",
"    ]. The impact of PEM on dialysis outcome may lead to a paradoxical risk factor reversal or reverse epidemiology of risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Among dialysis patients, for example, a low (and not a high) body mass index or a low (and not a high) serum cholesterol concentration is associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/11,68,70\">",
"     11,68,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=see_link\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several investigators suggest that PEM is a consequence of chronic inflammatory processes in patients with ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/9,10,50\">",
"     9,10,50",
"    </a>",
"    ]. Although proinflammatory cytokines may be a common link between malnutrition and inflammation, additional factors such as oxidative stress, carbonyl stress, uremic toxins, and others may also play roles [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Thus, the degree to which there is a link between PEM and inflammation and the independent effect of each upon adverse outcomes in patients with kidney diseases are currently unclear.",
"   </p>",
"   <p>",
"    The following two sections provide an overview of the data for and against a relationship between inflammation and malnutrition:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Positive observations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothesis that PEM is a consequence of chronic inflammatory processes in patients with ESRD is supported by the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/9,10,50\">",
"     9,10,50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammation is associated with a rise in plasma and probably tissue levels of catabolic cytokines; plasma elevations of inflammatory proteins and catabolic cytokines are commonly observed in non-dialyzed patients with advanced chronic renal insufficiency and in dialysis patients. One such cytokine, tumor necrosis factor alpha (TNF-alpha), promotes catabolic processes (engendering both protein degradation and suppression of protein synthesis) and induces anorexia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/11,71\">",
"       11,71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some dialysis patients with chronic inflammation develop weight loss and a negative protein balance, despite an intact appetite. In this setting, there may be a shift in protein synthesis from muscle to acute-phase proteins as renal function declines. Such patients also appear to lose more body weight during dialysis when compared to those without discernible inflammatory processes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Albumin synthesis is suppressed when serum CRP is elevated [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/10,50\">",
"       10,50",
"      </a>",
"      ]. In CRF patients, serum albumin decreases and proinflammatory cytokines accumulate as renal function deteriorates [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/14-16,73,74\">",
"       14-16,73,74",
"      </a>",
"      ]. Among well-dialyzed patients, activation of the acute phase response also correlates with lower serum albumin levels due to decreased albumin synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inflammation may lead to hypocholesterolemia, a strong mortality risk factor in dialysis patients and a marker of poor nutritional status [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/70,76\">",
"       70,76",
"      </a>",
"      ]. This was best shown in a prospective study of 823 patients who were categorized by either the presence or absence of",
"      <span class=\"nowrap\">",
"       inflammation/malnutrition,",
"      </span>",
"      which was defined by a low serum albumin concentration or elevated levels of CRP or interleukin-6 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/70\">",
"       70",
"      </a>",
"      ]. Among all patients as well as those with inflammation, lower cholesterol levels were associated with higher mortality. By comparison, higher cholesterol levels in those without markers of",
"      <span class=\"nowrap\">",
"       inflammation/malnutrition",
"      </span>",
"      were associated with higher mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, chronic inflammation may be a principal factor that causally links PEM to increased morbidity and mortality among dialysis patients. The term \"malnutrition-inflammation-complex syndrome\" (MICS) suggests the purported close association between PEM and inflammation in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/11,77,78\">",
"     11,77,78",
"    </a>",
"    ]. Alternatively, \"Malnutrition-Inflammation-Atherosclerosis\" (MIA) has been used to emphasize the importance of atherosclerotic diseases as a major consequence of the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several scoring systems have been proposed to assess the degree of MICS or MIA in dialysis patients, such as the \"malnutrition-inflammation score\" (MIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/77\">",
"     77",
"    </a>",
"    ]. This correlates strongly with both measures of nutritional status and inflammation and anemia.",
"   </p>",
"   <p>",
"    The MIS is also significantly associated with hospitalization rates and mortality in HD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/77\">",
"     77",
"    </a>",
"    ], since it is essentially a modified version of the Subjective Global Assessment of Nutrition (SGA) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/49\">",
"     49",
"    </a>",
"    ]; the SGA is recommended in the National Kidney Foundation",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines to be used routinely to assess the nutritional status of dialysis patients. The SGA also helps measure the degree of inflammation and illness severity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/49,77\">",
"     49,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Negative observations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also evidence that does not support inflammation as the principal cause of PEM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum albumin and prealbumin levels and other indicators of protein-energy nutritional status obviously correlate with protein intake and are independent of inflammatory status [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/80\">",
"       80",
"      </a>",
"      ]. The serum albumin decreases only modestly among normal individuals with PEM induced by reducing their nutrient intake or in malnourished HD patients fed low protein diets, suggesting that serum albumin is a direct reflection of protein intake [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/74,81,82\">",
"       74,81,82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In dialysis patients, the association of serum albumin and CRP is hardly precise, with the reported correlation coefficients usually less than 0.50 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/74,81\">",
"       74,81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unlike serum CRP levels, serum albumin concentrations usually do not fluctuate on a month-to-month basis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In some studies, the provision of adequate nutrition without management of inflammation improves hypoalbuminemia and clinical outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/83,84\">",
"       83,84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These considerations, although not conclusive, indicate that factors other than the catabolic consequences of inflammation also affect serum albumin and other nutritional measures. Nutrient intake is obviously one such factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Malnutrition may lead to inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also some data suggesting that malnutrition can lead to inflammation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malnourished dialysis patients may be deficient of antioxidants such as vitamin C or carotenoids [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/28\">",
"       28",
"      </a>",
"      ], which may lead to increased oxidative stress and inflammation.",
"     </li>",
"     <li>",
"      PEM may decrease host resistance and predispose to infection, which is clearly an inflammatory disorder. Certain nutrients, such as arginine and glutamine, may enhance the immune response [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/85\">",
"       85",
"      </a>",
"      ]. Moreover, preliminary data suggest that levocarnitine may protect against endotoxins and also suppress elaboration of TNF-alpha from monocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypocholesterolemia, as a reflection of general hypolipoproteinemia in malnourished dialysis patients, may mitigate the ability to remove circulating endotoxins. Based upon the lipoprotein-endotoxin hypothesis, there is an optimum serum lipoprotein concentration below which lipid reduction is detrimental because of the decreased ability of lipoproteins to bind lipopolysaccharide; this, in turn, may prevent lipoproteins from decreasing the detrimental effects of endotoxin [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;PEM may be associated with a poor outcome in dialysis patients because of inflammation. However, existing data are consistent with the possibility that nutrient intake may also independently affect outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CHRONIC INFLAMMATION AND OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased levels of markers of inflammation and malnutrition predict a poor outcome in patients with ESRD and CRF. Despite this, neither infection, which usually leads to an overt inflammatory response, or malnutrition are common causes of death. Rather, most individuals with chronic renal failure die of cardiovascular diseases (CVD). Thus, the purported link from underlying inflammation to decreased survival among renal patients, if it exists, should be most strongly observed for inflammation and atherosclerosis, rather than for inflammation and infection or malnutrition.",
"   </p>",
"   <p>",
"    Perhaps the best evidence supporting the importance of inflammation in the pathogenesis of atherosclerosis comes from the observation among patients without renal disease that markers of increased or decreased systemic inflammation are directly associated with an enhanced risk of atherosclerosis.",
"   </p>",
"   <p>",
"    Although the evidence is less clear, ESRD patients with coronary heart disease and enhanced cardiovascular risk and mortality frequently have similar elevated levels of acute phase reactants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased serum CRP levels in ESRD patients are as strong a predictor of cardiovascular mortality as serum albumin concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/1,2,88\">",
"       1,2,88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased serum levels of Interleukin-6 are associated with increased dialysis mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/76\">",
"       76",
"      </a>",
"      ], and progression of carotid atherosclerosis during dialysis may be related to increased IL-6 levels [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increasing clinical evidence also suggests that inflammation and oxidation stress are associated with adverse outcomes among predialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/90-94\">",
"     90-94",
"    </a>",
"    ]. This was perhaps best shown in a prospective study of 80 nondiabetic predialysis patients in which the effect of different conventional and nonconventional risk factors on cardiovascular events was examined [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/93\">",
"     93",
"    </a>",
"    ]. At follow-up at a median period of seven years, 21 patients developed adverse outcomes due to coronary, cerebral, or peripheral artery occlusion. Upon multivariate analysis, an adverse cardiovascular outcome was independently associated with increased age, and elevated CRP, fibrinogen, and advanced oxidation protein product levels.",
"   </p>",
"   <p>",
"    One study described the role of chemokines (8-14 kDa proteins which regulate leukocyte trafficking during inflammatory reactions) in the all-cause and cardiovascular mortality associated with elevated CRP levels in ESRD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. In this Mendelian randomization study of Dutch and Swedish dialysis patients there was a statistical interaction between the presence of a nonfunctioning allele of the chemokine receptor 5 (CCR5) and all-cause and cardiovascular mortality associated with elevated C-reactive protein (CRP) level. Patients with the allele appeared unaffected by the higher cardiovascular mortality seen in association with elevated CRP, interpreted as a potential protective effect by the nonfunctioning gene. Noncardiovascular mortality appeared increased in patients with higher CRP levels irrespective of their CCR5 polymorphism, consistent with the hypothesis that CCR5 is involved in the process of atherosclerosis, but also suggesting that the effects of inflammation may reach beyond the process of atherosclerosis and affect non-cardiovascular mortality as well as cardiovascular mortality in ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to atherosclerosis, inflammation may cause other adverse outcomes in renal disease such as refractory anemia, laboratory signs of iron overload, or a poor quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Inflamed dialysis patients frequently display increased serum ferritin, which is a positive acute phase reactant and an indicator of increased iron burden [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Serum ferritin levels correlate with hospitalization rates, and a recent increase in serum ferritin concentration in hemodialysis patients may be associated with an enhanced risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies, however, have not found an association between",
"    <span class=\"nowrap\">",
"     malnutrition/inflammation",
"    </span>",
"    and an increased risk of atherosclerosis among dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Among over 50,000 incident Medicare dialysis patients, for example, there was no association between body mass indices (BMI) suggestive of poor nutritional status and adverse cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/101\">",
"     101",
"    </a>",
"    ]. These findings suggest that markers other than BMI, such as a subjective global assessment, may be preferable when assessing a poor nutritional state in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation directly resulting from a specific identified source, such as an ongoing chronic infection, should be aggressively treated with targeted therapy. By comparison, the indications for the use of nonspecific measures to possibly help reduce chronic inflammatory processes are less clear.",
"   </p>",
"   <p>",
"    Although epidemiological evidence links inflammation to poor outcome in individuals with renal insufficiency, there are no randomized clinical trials to suggest that outcomes are improved by nonspecific inflammation-reducing modalities. There is therefore no consensus upon a uniform or standardized strategy for the treatment of chronic inflammation in patients with renal insufficiency.",
"   </p>",
"   <p>",
"    Despite this, the 2005",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines suggest that the assessment of CRP levels to help assess the presence of underlying inflammation would be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/103\">",
"     103",
"    </a>",
"    ]. The presence of increased levels, usually defined as a serum level greater than 5 to 10",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    may help predict cardiovascular risk.",
"   </p>",
"   <p>",
"    If utilized, treatment modalities may target inflammation directly or ameliorate oxidative stress or endothelial dysfunction. The following agents have been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Statins decrease CRP levels, independent of their effects on lipids [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/106-108\">",
"       106-108",
"      </a>",
"      ]. A prospective randomized placebo-controlled study of 34 dialysis patients reported that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      after six months, significantly lowered serum C-reactive protein (9 and 5",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      and cholesterol concentrations (175 and 156",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      and increased serum albumin levels (3.69 and 3.99",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/106\">",
"       106",
"      </a>",
"      ]. Early data suggested that the use of statins have been associated with decreased mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/109\">",
"       109",
"      </a>",
"      ], but two subsequent large clinical trials have failed to show a benefit of treatment with atorvastatin [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/110\">",
"       110",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/111\">",
"       111",
"      </a>",
"      ] on clinical end points in chronic hemodialysis patients. This was in spite of an 11.5 percent decrease in high sensitivity CRP levels in patients treated with rosuvastatin in the AURORA study [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/111\">",
"       111",
"      </a>",
"      ], raising doubts about the significance of CRP in cardiovascular morbidity and mortality in this patient population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=see_link\">",
"       \"Statins and chronic kidney disease\"",
"      </a>",
"      .) A third study (SHARP) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/112\">",
"       112",
"      </a>",
"      ], is examining the effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      on clinical end points in patients with various stages of CKD (dialysis and non-dialysis dependent), and is scheduled to release its findings later this year. The SHARP study will be the largest clinical trial ever conducted in patients with CKD and should provide conclusive answers to the questions surrounding the role of statin therapy in patients with ESRD and CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ACE inhibitors and angiotensin receptor blockers are used primarily as antihypertensive agents, but some of their benefits in patients with CKD and heart failure may be related to effects that are independent from their blood pressure-lowering mechanism. One such mechanism is an anti-inflammatory effect. Although the data are inconsistent, ACE inhibitors may have anti-inflammatory properties in both the general population and in those with chronic renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/113,114\">",
"       113,114",
"      </a>",
"      ]. Their utility to treat inflammation has not been formally studied in CKD patients.",
"     </li>",
"     <li>",
"      Since oxidative stress contributes to inflammation in CKD, anti-oxidants may lower the incidence of cardiovascular events in hemodialysis patients. High dose vitamin E was found to lower the risk of cardiovascular events in a small clinical trial in patients on dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/115\">",
"       115",
"      </a>",
"      ]. The use of vitamin C infusion and of vitamin E coated dialyzers in hemodialysis patients was also shown to reduce oxidative stress [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/116\">",
"       116",
"      </a>",
"      ], but there have been no clinical trials to examine the effect of such interventions on hard clinical end points. Another small study in dialysis patients showed that treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      lowered the incidence of cardiac events [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/117\">",
"       117",
"      </a>",
"      ]. It is unclear to what extent the beneficial effects associated with the use of these antioxidants is related to their anti-inflammatory effect. The feasibility and safety of these agents await testing in larger studies.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"       Sevelamer",
"      </a>",
"      hydrochloride is a cationic polymer that is used in patients with ESRD as an intestinal phosphate binder. This agent also possesses \"pleiotropic\" effects that are unrelated to phosphate binding; one such effect may be the amelioration of inflammation. Sevelamer lowered CRP in some [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/118,119\">",
"       118,119",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/120\">",
"       120",
"      </a>",
"      ], studies.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      is a glycosaminoglycan used as an anticoagulant and has been recognized for its antiinflammatory properties; this appears to be distinct from its anticoagulant activity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/121\">",
"       121",
"      </a>",
"      ]. It was proposed that new agents could be developed that retain the antiinflammatory properties of heparin but without the anticoagulant effects [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/121,122\">",
"       121,122",
"      </a>",
"      ]. In our opinion, the practical impact of a heparin-related antiinflammatory effect in the ESRD population is questionable, given that heparin is already routinely applied as an anticoagulant with hemodialysis, yet chronic inflammation is still very common in these patients.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       Megestrol acetate",
"      </a>",
"      is a synthetic derivate of progesterone used as an appetite stimulant. This agent also inhibits the activity of IL-1, IL-6, and TNF-alfa [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/123-127\">",
"       123-127",
"      </a>",
"      ]. The beneficial effects of megestrol acetate in ESRD patients are related to its appetite stimulant effects and include improved appetite, increased energy and protein intake, and increased dry weight and quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/128-130\">",
"       128-130",
"      </a>",
"      ]. The following side-effects limit its usefulness: headaches, dizziness, confusion, diarrhea, hyperglycemia, thromboembolic phenomena, breakthrough uterine bleeding, peripheral edema, hypertension, adrenal suppression, and adrenal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/123\">",
"       123",
"      </a>",
"      ]. This agent has not been studied as an antiinflammatory agent in CKD patients.",
"     </li>",
"     <li>",
"      Bardoxolone methyl (RTA 402) is an Antioxidant Inflammation Modulator (AIM) in clinical development for inflammation and cancer-related indications. It inhibits immune-mediated inflammation by restoring redox homeostasis in inflamed tissues through the induction of the cytoprotective transcription factor Nrf2 and suppresses the activities of the pro-oxidant and pro-inflammatory transcription factors NF-kB and the signal transducers and activators of transcription (STATs). In vivo, bardoxolone has shown significant anti-inflammatory activity in various animal models of inflammation such as renal damage in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      model and ischemia-reperfusion model of acute renal injury. This agent is currently undergoing Phase II clinical trials to assess its ability to slow progression of kidney disease in patients with advanced diabetic nephropathy (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"       Clinicaltrials.gov",
"      </a>",
"      NCT 00811889).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the above agents with complex mechanisms of action, there are multiple \"designer\" drugs that target a specific aspect of the inflammatory cascade. These drugs have applications mainly in rheumatoid arthritis, and most of them will likely not be utilized in patients with CKD. However, some agents are considered for patients with CKD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      &mdash; Etanercept is an anti-TNF agent that is effective in the treatment of various forms of inflammatory arthritis, such as rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis. In a pilot study involving 10 chronic hemodialysis patients, the administration of etanercept over 44 weeks appeared safe, but resulted only in small improvement in prealbumin concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/131\">",
"       131",
"      </a>",
"      ]. The effectiveness of etanercept in improving serum albumin and CRP levels of hemodialysis patients is being studied in a phase II randomized, double-blind, placebo-controlled clinical trial [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pentoxiphylline &mdash; Pentoxiphylline is a non-specific phosphodiesterase inhibitor that inhibits TNF transcription [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/133\">",
"       133",
"      </a>",
"      ]. Pentoxiphylline will be tested in ESRD patients in a randomized, double-blinded, placebo-controlled clinical trial [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/134\">",
"       134",
"      </a>",
"      ]. The Anti-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients (AIONID) study is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and will examine the effect of oral nutritional supplements with antiinflammatory and antioxidant properties along with pentoxiphylline therapy in a factorial design on malnutrition and inflammation in 100 patients receiving maintenance hemodialysis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       Anakinra",
"      </a>",
"      &mdash; Anakinra is a human recombinant IL-1 receptor antagonist that is used in rheumatoid arthritis. It also shows some promise in the treatment of inflammation in patients with CKD. A single study examined the pharmacokinetics of this drug in patients with impaired renal function, showing that the main route of elimination for anakinra is renal clearance and that hemodialysis has a very small effect on clearance [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/135\">",
"       135",
"      </a>",
"      ]. The results of this study indicate that thrice weekly dosing of anakinra may be possible. The safety and efficacy of anakinra chronic hemodialysis patients is currently examined in a randomized controlled clinical trial [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/136\">",
"       136",
"      </a>",
"      ]. This study examines the effect of anakinra on muscle protein breakdown, serum CRP level and whole body protein turnover. A future study will examine the effects of anakinra on inflammatory markers, endothelial function, oxidative stress, insulin resistance, pulse wave velocity, urinary cytokines and proteinuria in patients with nondialysis dependent CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/137\">",
"       137",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      &mdash; Rituximab is a B cell depleting monoclonal anti-CD20 antibody [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/138\">",
"       138",
"      </a>",
"      ]. B cell depletion affects the levels of autoantibodies that play important roles in the pathophysiology of diseases such as rheumatoid factor in RA [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/139,140\">",
"       139,140",
"      </a>",
"      ], systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/141\">",
"       141",
"      </a>",
"      ], and ANCA-associated vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/142-144\">",
"       142-144",
"      </a>",
"      ]. Rituximab also has been examined for the treatment of various glomerular diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/145-149\">",
"       145-149",
"      </a>",
"      ]. It is unclear if this agent will be employed for the treatment of chronic inflammation in CKD, since the autoantibody depletion resultant after B cell depletion may be more specific to certain types of diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Optimization of dialysis treatment may also improve inflammatory status in dialysis patients, with the type of dialysis membrane possibly having an impact upon mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/150\">",
"     150",
"    </a>",
"    ]. As an example, the use of biocompatible membranes decrease serum levels of CRP, although such interventions may not completely normalize its serum concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=see_link\">",
"     \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a major clinical trial, known as the HEMO study, failed to show a major improvement in clinical outcomes with the use of high-flux membranes. Nevertheless, this finding does not necessarily refute a role of dialysis membranes in the development of chronic inflammation in ESRD patients, since the membrane effect on survival may have been small compared with that of other variables.",
"   </p>",
"   <p>",
"    Currently, there is no consensus as to which medication or combination of drugs should be used under different clinical conditions. In general, ACE inhibitors are commonly used in CRF or ESRD patients with hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heart failure, statins are used in those with hyperlipidemia, and vitamin E in patients with refractory muscle cramps. Clinical trials have not been performed to determine whether the use of these medications is warranted for the treatment of inflammation in patients with renal dysfunction but without an indicated concurrent comorbid condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     NOVEL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novel treatment strategies are needed to help manage inflammation among patients with renal disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional anti-inflammatory and anticytokine agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      , should be tested in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/104,151\">",
"       104,151",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Randomized clinical trials are needed to compare the effect of anti-inflammatory agents with that of nutritional support in patients suffering from the MIC syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/78,104\">",
"       78,104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limited evidence suggests that resistance training may help reduce the MIC syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?23/37/24154/abstract/152\">",
"       152",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723076319\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic inflammatory processes are common in individuals with chronic kidney disease (CKD), including those with early stage CKD and especially end-stage renal disease (ESRD). This is due to many underlying factors, including the uremic milieu, elevated levels of circulating proinflammatory cytokines, oxidative stress, carbonyl stress, protein-energy wasting, enhanced incidence of infections (especially dialysis-access related) and others. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Inflammation and kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine monitoring of inflammatory markers in all ESRD or CKD patients is currently not recommended by most guidelines, although it may improve patient management. Periodic measurement of CRP or IL-6 to assess severity and frequency of inflammation is reasonable in select patients as part of an individualized workup prompted by specific clinical characteristics, such as protein-energy wasting. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'General markers of inflammation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of elevated inflammatory markers (eg, CRP&gt;5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      or 0.5",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      in ESRD or CKD patients should prompt a search for immediately treatable causes of acute or chronic inflammation, such as occult infections, volume overload, inadequate dialysis treatment, protein-energy wasting or the presence of a nonfunctioning renal allograft. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Management issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Currently no pharmacological interventions are recommended to target specifically chronic inflammation. However, several pharmacological and nutritional interventions are undergoing early clinical trials for this indication. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Management issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Novel approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/1\">",
"      Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/2\">",
"      Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/3\">",
"      Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/4\">",
"      Zoccali C, Benedetto FA, Mallamaci F, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 2000; 18:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/5\">",
"      Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999; 14:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/6\">",
"      Noh H, Lee SW, Kang SW, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998; 18:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/7\">",
"      Kalantar-Zadeh K. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: What is next? Semin Dial 2005; 18:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/8\">",
"      Kalantar-Zadeh K. Inflammatory marker mania in chronic kidney disease: pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol 2007; 2:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/9\">",
"      Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002; 13 Suppl 1:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/10\">",
"      Kaysen GA, Dubin JA, M&uuml;ller HG, et al. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002; 61:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/11\">",
"      Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001; 38:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/12\">",
"      Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993; 150:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/13\">",
"      Poole S, Bird TA, Selkirk S, et al. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 1990; 2:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/14\">",
"      Panichi V, Migliori M, De Pietro S, et al. C reactive protein in patients with chronic renal diseases. Ren Fail 2001; 23:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/15\">",
"      Stenvinkel P, Heimb&uuml;rger O, Wang T, et al. High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis 1999; 34:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/16\">",
"      Chung SH, Heimb&uuml;rger O, Stenvinkel P, et al. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001; 16:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/17\">",
"      Pecoits-Filho R, Heimb&uuml;rger O, B&aacute;r&aacute;ny P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/18\">",
"      Hasper D, Hummel M, Kleber FX, et al. Systemic inflammation in patients with heart failure. Eur Heart J 1998; 19:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/19\">",
"      Sato Y, Takatsu Y, Kataoka K, et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol 1999; 22:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/20\">",
"      Sharma R, Bolger AP, Li W, et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol 2003; 92:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/21\">",
"      Locatelli F, Canaud B, Eckardt KU, et al. The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 2003; 18:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/22\">",
"      Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/23\">",
"      Spittle MA, Hoenich NA, Handelman GJ, et al. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001; 38:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/24\">",
"      Mezzano D, Pais EO, Aranda E, et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/25\">",
"      Stenvinkel P, Holmberg I, Heimb&uuml;rger O, Diczfalusy U. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. Nephrol Dial Transplant 1998; 13:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/26\">",
"      Miyata T, Ueda Y, Horie K, et al. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998; 53:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/27\">",
"      Suliman ME, Heimb&uuml;rger O, B&aacute;r&aacute;ny P, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/28\">",
"      Kalantar-Zadeh K, Kopple JD, Deepak S, et al. Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr 2002; 12:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/29\">",
"      Langlois M, Duprez D, Delanghe J, et al. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 2001; 103:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/30\">",
"      Deicher R, Ziai F, Bieglmayer C, et al. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/31\">",
"      Keane WF, Collins AJ. Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. Am J Kidney Dis 1994; 24:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/32\">",
"      Kshirsagar AV, Moss KL, Elter JR, et al. Periodontal disease is associated with renal insufficiency in the Atherosclerosis Risk In Communities (ARIC) study. Am J Kidney Dis 2005; 45:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/33\">",
"      Kaysen GA. C-reactive protein: a story half told. Semin Dial 2000; 13:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/34\">",
"      Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/35\">",
"      Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 2003; :S172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/36\">",
"      Chen LP, Chiang CK, Chan CP, et al. Does periodontitis reflect inflammation and malnutrition status in hemodialysis patients? Am J Kidney Dis 2006; 47:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/37\">",
"      Craig RG, Kotanko P, Kamer AR, Levin NW. Periodontal diseases--a modifiable source of systemic inflammation for the end-stage renal disease patient on haemodialysis therapy? Nephrol Dial Transplant 2007; 22:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/38\">",
"      Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/39\">",
"      Memoli B, Minutolo R, Bisesti V, et al. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis 2002; 39:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/40\">",
"      Ayus JC, Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 1998; 9:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/41\">",
"      Cappelli G, Tetta C, Canaud B. Is biofilm a cause of silent chronic inflammation in haemodialysis patients? A fascinating working hypothesis. Nephrol Dial Transplant 2005; 20:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/42\">",
"      Pecoits-Filho R, Stenvinkel P, Wang AY, et al. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 2004; 24:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/43\">",
"      Avram, MM, Fein, PA, Rafiz, MA, et al. Malnutrition and inflammation as predictors of mortality in peritoneal dialysis patients. Kidney Int 2006; 70(Suppl 104):S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/44\">",
"      Yeun JY, Kaysen GA. Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin in peritoneal dialysis patients. Am J Kidney Dis 1997; 30:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/45\">",
"      L&oacute;pez-G&oacute;mez JM, P&eacute;rez-Flores I, Jofr&eacute; R, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/46\">",
"      Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998; 54:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/47\">",
"      Streetz KL, W&uuml;stefeld T, Klein C, et al. Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) 2001; 47:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/48\">",
"      Suffredini AF, Fantuzzi G, Badolato R, et al. New insights into the biology of the acute phase response. J Clin Immunol 1999; 19:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/49\">",
"      Kalantar-Zadeh K, Kleiner M, Dunne E, et al. Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 1998; 31:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/50\">",
"      Kaysen GA, Dubin JA, M&uuml;ller HG, et al. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 2000; 58:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/51\">",
"      Stenvinkel P, Barany P, Heimb&uuml;rger O, et al. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 2002; :103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/52\">",
"      Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/53\">",
"      Panichi V, Maggiore U, Taccola D, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/54\">",
"      Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2006; 48:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/55\">",
"      Tong M, Carrero JJ, Qureshi AR, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007; 2:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/56\">",
"      Muntinghe FL, Verduijn M, Zuurman MW, et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 2009; 20:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/57\">",
"      Ducloux D, Bresson-Vautrin C, Kribs M, et al. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002; 62:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/58\">",
"      Pecoits-Filho R, B&aacute;r&aacute;ny P, Lindholm B, et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/59\">",
"      Wang AY, Woo J, Lam CW, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003; 14:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/60\">",
"      Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/61\">",
"      Wang AY, Wang M, Woo J, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/62\">",
"      Rao M, Guo D, Perianayagam MC, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005; 45:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/63\">",
"      Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant 2003; 18:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/64\">",
"      Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 2008; 3:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/65\">",
"      Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:3070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/66\">",
"      Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/67\">",
"      Kopple JD. Nutritional status as a predictor of morbidity and mortality in maintenance dialysis patients. ASAIO J 1997; 43:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/68\">",
"      Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/69\">",
"      Kalantar-Zadeh K, Abbott KC, Kronenberg F, et al. Epidemiology of dialysis patients and heart failure patients. Semin Nephrol 2006; 26:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/70\">",
"      Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/71\">",
"      Flores EA, Bistrian BR, Pomposelli JJ, et al. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 1989; 83:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/72\">",
"      Kaizu Y, Kimura M, Yoneyama T, et al. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998; 31:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/73\">",
"      Kopple JD, Greene T, Chumlea WC, et al. Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int 2000; 57:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/74\">",
"      Kaysen GA, Chertow GM, Adhikarla R, et al. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001; 60:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/75\">",
"      Kaysen GA, Dubin JA, M&uuml;ller HG, et al. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int 2004; 65:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/76\">",
"      Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/77\">",
"      Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001; 38:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/78\">",
"      Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/79\">",
"      Stenvinkel P, Heimb&uuml;rger O, Lindholm B, et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/80\">",
"      Pupim LB, Caglar K, Hakim RM, et al. Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int 2004; 66:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/81\">",
"      Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997; 29:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/82\">",
"      Ginn HE, Frost A, Lacy WW. Nitrogen balance in hemodialysis patients. Am J Clin Nutr 1968; 21:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/83\">",
"      Leon JB, Majerle AD, Soinski JA, et al. Can a nutrition intervention improve albumin levels among hemodialysis patients? A pilot study. J Ren Nutr 2001; 11:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/84\">",
"      Leon JB, Albert JM, Gilchrist G, et al. Improving albumin levels among hemodialysis patients: a community-based randomized controlled trial. Am J Kidney Dis 2006; 48:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/85\">",
"      Hulsew&eacute; KW, van Acker BA, von Meyenfeldt MF, Soeters PB. Nutritional depletion and dietary manipulation: effects on the immune response. World J Surg 1999; 23:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/86\">",
"      De Simone C, Famularo G, Tzantzoglou S, et al. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral L-carnitine. AIDS 1994; 8:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/87\">",
"      Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/88\">",
"      deFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/89\">",
"      Stenvinkel P, Heimb&uuml;rger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002; 39:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/90\">",
"      Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/91\">",
"      Chauveau P, Chadefaux B, Coud&eacute; M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 1993; 41:S72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/92\">",
"      Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/93\">",
"      Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/94\">",
"      Kovesdy CP, George SM, Anderson JE, Kalantar-Zadeh K. Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. Am J Clin Nutr 2009; 90:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/95\">",
"      Kovesdy CP, Kalantar-Zadeh K. Do genes allow inflammation to kill or not to kill? J Am Soc Nephrol 2009; 20:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/96\">",
"      Muntinghe FL, Verduijn M, Zuurman MW, et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 2009; 20:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/97\">",
"      Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 2001; 12:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/98\">",
"      Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/99\">",
"      Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2001; 37:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/100\">",
"      Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/101\">",
"      Beddhu S, Pappas LM, Ramkumar N, Samore MH. Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol 2004; 15:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/102\">",
"      Stenvinkel P, Heimb&uuml;rger O, Lindholm B. Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant 2004; 19:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/103\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/104\">",
"      Guarnieri G, Biolo G, Zanetti M, Barazzoni R. Chronic systemic inflammation in uremia: potential therapeutic approaches. Semin Nephrol 2004; 24:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/105\">",
"      Kovesdy CP, Kalantar-Zadeh K. Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease. Expert Opin Investig Drugs 2008; 17:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/106\">",
"      Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004; 43:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/107\">",
"      Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/108\">",
"      Kumar S, Raftery M, Yaqoob M, Fan SL. Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients. Perit Dial Int 2007; 27:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/109\">",
"      Chang JW, Yang WS, Min WK, et al. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/110\">",
"      Wanner C, Krane V, M&auml;rz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/111\">",
"      Fellstr&ouml;m BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/112\">",
"      Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003; :S207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/113\">",
"      Stenvinkel P, Andersson P, Wang T, et al. Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 1999; 246:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/114\">",
"      Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol 2003; 284:F863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/115\">",
"      Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/116\">",
"      Yang CC, Hsu SP, Wu MS, et al. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int 2006; 69:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/117\">",
"      Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/118\">",
"      Ferramosca E, Burke S, Chasan-Taber S, et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/119\">",
"      Yamada K, Fujimoto S, Tokura T, et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 2005; 27:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/120\">",
"      Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/121\">",
"      Tyrrell DJ, Horne AP, Holme KR, et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/122\">",
"      Lever R, Hoult JR, Page CP. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 2000; 129:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/123\">",
"      Bossola M, Muscaritoli M, Tazza L, et al. Malnutrition in hemodialysis patients: what therapy? Am J Kidney Dis 2005; 46:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/124\">",
"      Lambert CP, Sullivan DH, Evans WJ. Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial. J Gerontol A Biol Sci Med Sci 2003; 58:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/125\">",
"      Mantovani G, Macci&ograve; A, Lai P, et al. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog 1998; 9:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/126\">",
"      Mantovani G. Does megestrol acetate down-regulate interleukin-6 in patients? Support Care Cancer 2002; 10:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/127\">",
"      Yeh SS, Wu SY, Levine DM, et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. J Gerontol A Biol Sci Med Sci 2001; 56:M48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/128\">",
"      Boccanfuso JA, Hutton M, McAllister B. The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr 2000; 10:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/129\">",
"      Burrowes JD, Bluestone PA, Wang J, Pierson RN Jr. The effects of moderate doses of megestrol acetate on nutritional status and body composition in a hemodialysis patient. J Ren Nutr 1999; 9:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/130\">",
"      Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr 2005; 15:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/131\">",
"      Don BR, Kim K, Li J, et al. The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol 2010; 73:431.",
"     </a>",
"    </li>",
"    <li>",
"     www.clinicaltrials.gov/ (Accessed on June 2, 2008). Identifier: NCT 00293202.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/133\">",
"      Kiely PD, Gillespie KM, Oliveira DB. Oxpentifylline inhibits tumor necrosis factor-alpha mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats. Eur J Immunol 1995; 25:2899.",
"     </a>",
"    </li>",
"    <li>",
"     www.clinicaltrials.gov/ (Accessed on June 2, 2008). Identifier: NCT 00561093.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/135\">",
"      Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003; 74:85.",
"     </a>",
"    </li>",
"    <li>",
"     Identifier: NCT 00420290. www.clinicaltrials.gov (Accessed on July 28, 2010).",
"    </li>",
"    <li>",
"     Identifier: NCT 00897715. www.clinicaltrials.gov (Accessed on July 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/138\">",
"      Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/139\">",
"      Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/140\">",
"      Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/141\">",
"      Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54:3612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/142\">",
"      Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/143\">",
"      Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/144\">",
"      Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54:2970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/145\">",
"      Kamar N, Faguer S, Esposito L, et al. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 2007; 67:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/146\">",
"      Milovanova SIu, Lopatkina TN, Kozlovskaia LV, Krasnova TN. [Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of HCV-associated severe cryoglobulinemic glomerulonephritis]. Ter Arkh 2007; 79:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/147\">",
"      Ponticelli C. New therapies for lupus nephritis. Clin J Am Soc Nephrol 2006; 1:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/148\">",
"      Ruggenenti P, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006; 1:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/149\">",
"      Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/150\">",
"      Bloembergen WE, Hakim RM, Stannard DC, et al. Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis 1999; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/151\">",
"      Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276:22382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/37/24154/abstract/152\">",
"      Castaneda C, Gordon PL, Parker RC, et al. Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 2004; 43:607.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1939 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-2A3F076F4F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24154=[""].join("\n");
var outline_f23_37_24154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H723076319\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFLAMMATION AND KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Decreased clearance of proinflammatory cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Volume overload, with endotoxinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Oxidative and carbonyl stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Decreased antioxidants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Presence of a failed kidney transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      GENERAL MARKERS OF INFLAMMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DOES INFLAMMATION LEAD TO MALNUTRITION?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Positive observations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Negative observations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Malnutrition may lead to inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CHRONIC INFLAMMATION AND OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      NOVEL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H723076319\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1939\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1939|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/2/37933\" title=\"table 1\">",
"      Inflammatory markers in CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/29/5595\" title=\"table 2\">",
"      Interpretations serum CRP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=related_link\">",
"      Clinical consequences of hemodialysis membrane biocompatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29190?source=related_link\">",
"      Contaminants in water used for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28005?source=related_link\">",
"      Diagnosis of iron deficiency in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20081?source=related_link\">",
"      Erythrocyte sedimentation rate in renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=related_link\">",
"      Pathogenesis and treatment of malnutrition in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=related_link\">",
"      Uremic toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41111?source=related_link\">",
"      Withdrawal of immunosuppression after renal transplant failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_37_24155="PUVA contraindications";
var content_f23_37_24155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications to PUVA phototherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Absolute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Xeroderma pigmentosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lupus erythematosus with photosensitivity or positive Ro antibody",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy (category C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Photosensitivity and/photosensitizing medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History or family history of melanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of nonmelanoma skin cancer and/or extensive solar damage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous treatment with ionizing radiation or arsenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe liver, renal, or cardiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Young age",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Morison WL. Phototherapy and Photochemotherapy of Skin Disease, 3rd ed, Taylor and Francis, New York 2005.",
"      </li>",
"      <li>",
"       Morison WL. PUVA Photochemotherapy. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, Philadelphia 2007.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24155=[""].join("\n");
var outline_f23_37_24155=null;
var title_f23_37_24156="Weight loss with Rx";
var content_f23_37_24156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F86128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F86128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Weight loss with various medications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"30%\">",
"     </colgroup>",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Length of trial",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phentermine",
"       </td>",
"       <td>",
"        13 weeks",
"       </td>",
"       <td>",
"        -6.4 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diethylpropion",
"       </td>",
"       <td>",
"        18 weeks",
"       </td>",
"       <td>",
"        -6.5 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mazindol",
"       </td>",
"       <td>",
"        11 weeks",
"       </td>",
"       <td>",
"        -5.7 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orlistat",
"       </td>",
"       <td>",
"        &ge;1 year",
"       </td>",
"       <td>",
"        -5.3 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoxetine",
"       </td>",
"       <td>",
"        24 weeks",
"       </td>",
"       <td>",
"        -4.8 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bupropion",
"       </td>",
"       <td>",
"        24 weeks",
"       </td>",
"       <td>",
"        -8.0 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exenatide",
"       </td>",
"       <td>",
"        24 weeks",
"       </td>",
"       <td>",
"        -2.9 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liraglutide",
"       </td>",
"       <td>",
"        24 weeks",
"       </td>",
"       <td>",
"        -2.8 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metformin",
"       </td>",
"       <td>",
"        1 year",
"       </td>",
"       <td>",
"        -2.8 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sibutramine",
"       </td>",
"       <td>",
"        &ge;1 year",
"       </td>",
"       <td>",
"        -6.4 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lorcaserin",
"       </td>",
"       <td>",
"        1 year",
"       </td>",
"       <td>",
"        -5.8 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phen/Topiramate",
"       </td>",
"       <td>",
"        &ge;1 year",
"       </td>",
"       <td>",
"        -10.2 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buprop/Naltrex",
"       </td>",
"       <td>",
"        &ge;1 year",
"       </td>",
"       <td>",
"        -8.7 kg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomized controlled trials. BMJ 2012; 344:d7771.",
"      </li>",
"      <li>",
"       LeBlanc ES, O'Connor E, Whitlock EP, et al. Effectiveness of primary care-relevant treatments for obesity in adults: A systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:434.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24156=[""].join("\n");
var outline_f23_37_24156=null;
var title_f23_37_24157="Meds associated with FTT";
var content_f23_37_24157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications associated with weight loss and failure to thrive",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Drugs that may cause anorexia",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Anticonvulsants",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Digoxin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Estrogens",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           H2 Blockers",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Hypnotics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Narcotics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           NSAIDS",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Proton-pump inhibitors",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Psychotropics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           SSRI's",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Thyroid replacements",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Drugs with adverse behavioral reactions",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Anticonvulsants",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Anti-cholinergics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Hypnotics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Narcotics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Psychotropics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Drugs that may alter taste",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           ACE inhibitors",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Allopurinol",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Antihistamines",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Beta 2 Agonists",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Clarithromycin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Coumadin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Digoxin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Eszopiclone",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Famotidine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Furosemide",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Lithium",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Metronidazole",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Nizatidine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Omeprazole",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Phenytoin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Sertraline",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Drugs associated with dysphagia",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           ACE inhibitors",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Antibiotics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Antihistamines",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Antivirals",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Ascorbic acid",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Bisphosphonates",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Diuretics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           KCl",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Narcotics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Nitrates",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           NSAIDS",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Psychotropics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Theophyllines",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Drugs with adverse GI reactions (excluding dysphagia)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Acetylcholinesterase inhibitors",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Amiodarone",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Antibiotics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Chemotherapy",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Digoxin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Ferrous Sulfate",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Laxatives",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           NSAIDS",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Quinidine",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goldberg, R, Physicians attentiveness to medication use as etiology of weight loss. Long-term Care interface 2005; 20. Copyright &copy;2005 Medicomint.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24157=[""].join("\n");
var outline_f23_37_24157=null;
var title_f23_37_24158="Contents: Skin and soft tissue surgery";
var content_f23_37_24158=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Skin and soft tissue surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Skin and soft tissue surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Benign skin lesions",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/1/44056\">",
"           Acquired melanocytic nevi (moles)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/17/43287\">",
"           Benign pigmented skin lesions other than melanocytic nevi (moles)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatologic surgery techniques",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/20/40264\">",
"           Skin biopsy techniques",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Desmoid tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/11/30906\">",
"           Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lymphedema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/31/29177\">",
"           Operative management of primary and secondary lymphedema",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Melanoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/17/7447\">",
"           Congenital melanocytic nevi and speckled lentiginous nevi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/7/36986\">",
"           Cutaneous complications of conventional chemotherapy agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/28/27081\">",
"           Cutaneous melanoma: Management of in transit metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34007\">",
"           Cutaneous melanoma: Management of local recurrence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/2/26664\">",
"           Evaluation and treatment of regional lymph nodes in melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/61/26585\">",
"           Initial surgical management of melanoma of the skin and unusual sites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39927\">",
"           Management of brain metastases in melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/59/8122\">",
"           Ocular melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/11/1206\">",
"           Pathologic evaluation of regional lymph nodes in melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/53/24410\">",
"           Risk factors for the development of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/15/35065\">",
"           Staging work-up and surveillance after treatment of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/8/2183\">",
"           Surgical management of metastatic melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/31/42488\">",
"           Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nail problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12758\">",
"           Nail surgery",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Non-melanoma skin cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/35/6712\">",
"           Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/31/3577\">",
"           Staging and treatment of Merkel cell carcinoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pressure ulcers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/20/34120\">",
"           Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/1/1049\">",
"           Prevention of pressure ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/12/37064\">",
"           Treatment of pressure ulcers",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sarcoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/23/33146\">",
"           Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/47/38650\">",
"           Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/40/44680\">",
"           Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/45/27354\">",
"           Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/53/24405\">",
"           Intergluteal pilonidal disease: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/42/4774\">",
"           Management of intergluteal pilonidal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/7/6265\">",
"           Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/44/24266\">",
"           Treatment of hidradenitis suppurativa",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-75BF23AB39-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f23_37_24158=[""].join("\n");
var outline_f23_37_24158=null;
var title_f23_37_24159="Predictive model for outcome after CABG";
var content_f23_37_24159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Predictive model for outcome after CABG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 585px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Preoperative factors can be used to predict in-hospital mortality and morbidity in patients who are undergoing coronary artery bypass graft surgery (CABG). These factors are given a risk score value (panel B). Based upon the total risk score, which varies from 0 to 73, patients can be stratified in deciles of risk (panel A). The predicted probability of a major adverse event correlates closely with the observed incidence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fortescue EB, Kahn K, Bates DW. Am J Cardiol; 88:1251.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_37_24159=[""].join("\n");
var outline_f23_37_24159=null;
